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Abstract
In recent years there has been a rapid growth in the understanding of the basic
cellular processes of individual bacterial cells through advances in molecular
biological research. However, this has introduced a demand to understand how the
interactions between the individual system components contribute to the overall
population dynamics. A useful theoretical approach for relating information at the
individual cellular/molecular level with emergent population characteristics is the
agent-based (or individual-based) modelling approach. The agent-based modelling
approach involves assigning pre-defined rules and parameters to each individual
component (e.g. the bacterial cell) of the population. Therefore, the emergent
behaviour of the population as a whole can be examined without the need for
population-level laws.
An agent-based model of bacterial population growth, called the Micro-Gen
Bacterial Simulator, has been developed to provide a theoretical framework for
investigating the interactions between antibiotics and bacterial cells in culture.
Parameters are inputted at the cellular level in order to replicate the life cycle of
bacteria grown in batch culture. The individual bacteria of a colony are represented
by software agents, which store the physical traits such as energy state or antibiotic
damage and the behavioural rules of the bacteria. The interactions of antibiotic
molecules with the bacterial cells and extra-cellular enzymes (e.g. β-lactamases)
are governed by defined kinetic rules derived from the biological literature.
The Minimum Inhibitory Concentration (MIC) was calculated from the model
for a number of common antibiotics, against methicillin-resistant S. aureus
(MRSA), and compared with real-world results. The predicted values from these
initial tests matched closely those recorded from in vitro experimental studies of
MRSA in the literature. The model was also used to examine the system dynamics
of the enzyme-catalysed therapeutic activation (ECTA) pro-drug delivery system,
a novel approach for achieving β-lactamase-mediated selective release of antimi-
crobial agents. It is thought that this strategy might be a promising approach for
treating β-lactamase over-expressing strains of bacteria that are resistant to tradi-
tional β-lactam antibiotics. The model provides a suitable theoretical framework
for comparing and contrasting different drug treatment strategies from a system’s
perspective in order to assess their potential efficacy.
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GLOSSARY
β-lactam Antibiotics Common class of antibiotics, characterised by
the presence of a β-lactam ring structure which
facilitates binding to the penicillin-binding pro-
teins in cell membrane of bacteria and disrupting
cell wall synthesis. Examples include penicillin
G, ampicillin and cephalothin, 15
β-lactamase Enzyme produced by bacterial cells which de-
grades β-lactam antibiotic molecules by cleaving
their β-lactam ring structure., 31
Staphylococcus aureus Non-motile species of bacteria that generally ex-
ist as part of the normal flora found on nasal pas-
sages, skin and mucous membranes in humans.
Have the potential to cause a variety of infec-
tions from superficial skin lesions such as boils,
to more serious conditions such as pneumonia,
15
12
Agent-Based Model Computational modelling approach which simu-
lates the actions and interactions of autonomous
individuals/agents. Rules and parameters are de-
fined at the individual-level rather than for the
population as a whole., 17
Antibiotic Resistance Refers to the ability of a microorganism to re-
sist the effects of an antibiotic. Examples of
mechanisms of antibiotic resistance include the
synthesis of antibiotic-degrading enzymes (e.g.
β-lactamase), and modifications to drug targets
such as the penicillin-binding proteins (PBPs) in
bacterial cell membranes, 33
BAIT Bacteria-Antibiotic Interaction Tool - precur-
sor to Micro-Gen, which implemented a simple
model of bacterial growth and interactions with
antibiotic molecules in discrete, 2D environment,
30
Chemotaxis The movement/orientation of a cell/organism ei-
ther towards (positive) or away from (negative) a
chemical stimulus, along a chemical concentra-
tion gradient, 48
13
MIC Minimum Inhibitory Concentration is the mini-
mum concentration of an antibiotic that results in
inhibition of bacterial growth in vitro for a spec-
ified period of time, 38
Micro-Gen Bacterial Simulator Agent-based model of bacteria-antibiotic interac-
tions in vitro. Uses basic cellular and kinetic pa-
rameters to explore the emergent population dy-
namics of antibiotic resistance, 7
Model A mathematical or computational model is a pur-
poseful representation of an entity or system
whose purpose is to capture the essence of a
problem and explore different solutions of it, 20
MRSA Methicillin-Resistant S. aureus - multi-drug re-
sistant form of S. aureus which was first isolated
in 1961. Resistance conferred by expression of
penicillin-binding protein 2a which has reduced
binding to β-lactam antibiotics, 32
Pro-drug A drug that is administered in a pharmacologi-
cally inactive (or significantly less active) form
and is then metabolised in vivo into an active
metabolite., 111
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CHAPTER 1
INTRODUCTION
1.1 Motivation
The emergence of multi-drug resistance in Staphylococcus aureus bacteria has be-
come a major healthcare problem in recent years. Prior to the introduction of antibi-
otics, patients with S. aureus bacteraemia had a mortality rate of over 80% [9]. This
situation improved dramatically when the first β-lactam antibiotic, penicillin, was
introduced into clinical use during the early 1940s [10]. However, today greater
than 95% of all S. aureus isolates possess resistance to penicillin, and 40-60% of
clinical isolates in the United States of America and the United Kingdom express
methicillin resistance (MRSA) [11, 12].
There has been a rapid increase in information about the basic cellular processes
that lead to antibiotic resistance due to advances in cell and molecular biology. This
development has allowed a finer-grained approach to investigating the spread of re-
sistance in populations of bacteria. However, the overall population response to
antibiotic treatment is often a function of a diverse range of interacting compo-
nents. In order to develop strategies to minimize the spread of antibiotic resistance,
a sound theoretical understanding of the systems of interactions taking place must
15
be developed. For example, there has been a rapid development in the field of phar-
macokinetic/pharmacodynamic studies in the last few decades that has led to a bet-
ter understanding of the complex dynamics that contribute to the bacterial response
to drug treatment [13]
There are a number of different approaches that have been taken to analyse
how populations of bacteria grow and interact. The most common approach is to
develop mathematical, or state variable, models that describe the population as a
whole. This can give important insights into parameters at the population-level
that influence the development of the colony [14]. These approaches are appro-
priate for developing an integrated view of colony development and benefit from
the fact that they are often less parameter-rich than other approaches. However,
the use of global parameters requires the implicit assumption that the population
is in a homogeneous, mixed environment. However, in nature, bacteria often form
highly heterogenous colonies where there can be significant localised variations in
the chemical environment such as ion concentrations, pH, temperature and nutrient
availability [15].
The approach taken here is to implement an agent-based (or individual-based)
model where the individual bacterial cells represent the fundamental units of the
simulation. This bottom-up approach means that parameters are defined for the
bacterial cells rather than for the population as a whole. The properties of a colony
thus emerge from the set of interactions of a population of heterogeneous bacte-
rial agents. Therefore, the inherent heterogeneity that exists in a bacterial colony
is explicitly modelled. Some of the drawbacks of this approach include the fact
that it can sometimes require more parameters than a state variable approach since
the individual entities are explicitly modelled and it also may become too open to
empirical knowledge [13]. However, by using appropriate aggregation of parame-
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ters in order to simplify the model, and cognisant of its limitations, the agent-based
approach can be used as a powerful tool for tracing back system behaviour to that
of its individual components.
A model has been developed called Micro-Gen that implements the agent-based
approach to simulate the life cycle of bacteria grown in culture and their interac-
tions with antibiotic molecules [16, 17, 18]. This model can be adapted to represent
different species and strains of bacteria using basic cellular information. For this
study, simulations were carried out using parameters applicable to MRSA. Micro-
Gen has been designed to incorporate the two main antibiotic resistance strategies
characteristic of MRSA. It is possible to produce a quantitative model of the inter-
actions between antibiotics and MRSA bacteria because the kinetic rules for these
reactions have been well characterized experimentally [19, 20]. The ability to sim-
ulate the individual molecular interactions of antibiotic molecules and bacteria, and
scale this up to large population sizes using the agent-based approach, is a powerful
tool for exploring the emergent dynamics that contribute to antibiotic resistance in
bacterial populations.
1.2 Objectives
The objective of the research is to develop an agent-based model of MRSA
that incorporates the main antibiotic resistance mechanisms found used by these
pathogenic bacteria. The model will be used to study the effects of changes at the
molecular level on the overall efficacy of existing antibiotics.
Our key objectives for attaining this goal were as follows:
1. Develop a robust, adaptable model of bacterial cellular growth in culture
which replicates the standard life cycle of bacteria. Validate the model for
17
the clinically important gram-positive bacterial species S. aureus.
2. Expand the model to include a detailed representation of the interactions be-
tween antibiotics and MRSA that incorporates the principal kinetic rules gov-
erning these interactions.
3. Use the model to examine the relationship between low-level cellu-
lar/biochemical properties of individual bacteria/antibiotics and high-level
treatment response at the population level. Assess the impact of the differ-
ent kinetic parameters on antibiotic treatment outcome.
4. Explore potential, novel drug delivery systems such as the pro-drug technol-
ogy and predict their efficacy using theoretical studies.
1.3 Outline of Thesis
The second chapter of the thesis gives an overview of existing approaches taken to
model bacterial growth and development, and compares the agent-based approach
to more traditional population-based mathematical models. Following this, a more
detailed overview of MRSA will be given and the antibiotic resistance strategies that
have been identified in it. The next chapter contains a detailed description of the
agent-based model Micro-Gen, which was developed to simulate the interactions of
anti-microbial drugs with bacteria in culture.
In chapters four and five, a detailed analysis of the system dynamics involved
in the interactions between anti-microbial drugs and MRSA is carried out. The ef-
fects of key cellular parameters associated with antibiotic-resistance mechanisms
on treatment outcome are also explored. The cellular and molecular parameters for
this model were derived from the biological literature for three different strains of
18
MRSA, and the model was used to predict the Minimum Inhibitory Concentration
(MIC, which is a key clinical measure of antibiotic efficacy) of each antibiotic ver-
sus the three strains. When the predicted MICs from the model were compared with
experimentally derived MICs for MRSA, they were found to be in close quantitative
agreement.
Chapter six details simulations to explore a novel drug delivery system called
the enzyme-catalysed therapeutic activation (ECTA) pro-drug delivery system and
illustrate the value of Micro-Gen in supporting drug discovery efforts. The final
sections of the thesis include the conclusions from the present research along with
future directions that may be taken, followed by a bibliography of relevant papers
in the field. Full copies of publications that have arisen out of the current research
are attached at the end of the thesis.
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CHAPTER 2
LITERATURE REVIEW
2.1 Computational Modelling of Bacteria
Computational systems biology is a swiftly developing field in biological simula-
tion that attempts to model complex biological processes as integrated systems of
interacting components, using data from genomic, proteomic, metabolomic and cel-
lular studies [21]. This often involves collecting large datasets of experimental data
to develop predictive computational models which are then assessed and compared
with newly derived experimental data in order to further improve the model and
give insights into the biological processes being observed.
The power of the computational modelling approaches is not so much in their
ability to make predictions (some degree of experimental validation will always
be needed to confirm any predictions) but in their ability to give new insights into
the underlying mechanistic basis for the observed biological phenomena. A com-
putational model may be defined as a ‘purposeful representation’ of an entity or
system whose “purpose is to capture the essence of a problem and explore differ-
ent solutions of it” [22]. The most important role of a model is therefore to aid in
our understanding of a particular process. From this perspective, all the different
20
modelling approaches share the same principal aim, though they may differ in the
assumptions and tools that are used.
There have been many different modelling approaches developed in computa-
tional systems biology that encompass many different temporal and spatial scales.
Complex biological processes can range from microscopic sub-cellular processes
such as cell metabolic pathways to large-scale ecological questions involving the
development of populations of organisms over long periods of time. For this rea-
son, many different modelling approaches, with differing granularity in their tem-
poral/spatial scales, have been developed to approach these problems. However,
many of them are adaptations of particular modelling strategies that use common
techniques such as ordinary differential equations or agent-based modelling tech-
niques to address their specific modelling questions.
2.1.1 Mathematical Approaches
A number of the most common simulation techniques used include mathematical
approaches such as ordinary differential equations (ODEs) and partial differential
equations (PDEs). ODE models are probably the most common modelling ap-
proach used in systems biology since they are computationally efficient and math-
ematically robust, and can be used to develop an integrated view of biological sys-
tems. Basic ordinary differential equation methods are limited in their ability to
model situations such as discontinuous state-changes, stochasticity, diffusion, com-
partmentalization and cell migration [23]. However, in order to address some of
these limitations extensions to the basic ODE methods have been developed such
as stochastic ODEs and compartmentalised ODE models. Basic ODEs are lim-
ited to temporal modelling, but partial differential equations (PDEs) can be used to
21
model processes that have spatial as well temporal dependencies.
Mathematical population models are commonly used to describe the growth
and development of a bacterial colony as a unit, using global parameters or state
variables [24, 14]. These “top-down” approaches have the advantage that they are
computationally efficient and less parameter-rich than more low-level approaches.
However, an important limitation of the state variable approach is that it does not
allow the user to trace back the system behaviour to the behaviour of the individual
agents. For example, this approach cannot explain the underlying factors that lead
to the population exhibiting a particular growth rate or carrying capacity [22]. How-
ever, they are important to provide an appropriate integrated view of the population
behaviour.
2.1.2 Petri Nets
Other techniques used in computational systems biology include Petri nets, cellular
automata, and finally, the approach used in this project, the agent-based approach.
Petri nets are an alternative approach to modelling time-dependent processes [23].
Petri nets consist of two types of node: a ‘place’ which can be used to represent,
for example, a particular species of molecule, and a ‘transition’ node, which might
represent reactions (Fig. 2.1). Petri nets are a discrete system which is driven by
implicit time increments where a transition ‘fires’ when the markings (or tokens)
at all of its ‘input’ places exceed the ‘weights’ on its input arcs, producing product
on its output arcs. This correlates with a reaction occurring when there are enough
reactant molecules, resulting in the generation of reaction products.
The Petri nets approach has been expanded to address more complex mod-
elling questions involving either discrete or continuous values (Hybrid Petri nets
22
P1
P2
P3
T1
P4
P5
Input
Arcs
Output
Arcs
Token
Figure 2.1: An example of a simple Petri net, consisting of input places (P1-P3),
output places (P4-P5), transition (T1), and arcs (input and output). Places can con-
tain tokens, and when there are enough tokens in the input places the transition
‘fires’, removing tokens from its input places and adding them to the output places.
and Functional Hybrid Petri nets). Coloured Petri nets have also been developed
that allow mathematical relationships to be incorporated in transitions to govern
the rate of firing. Petri nets can also be used to build compartmental models by
having different ‘places’ to represent the same chemical species in different com-
partments. For this reason, the Petri nets formalism represents a powerful tool for
qualitative and quantitative modelling of many biological processes [25]. However,
this approach is not as amenable to modelling spatially dependent processes such
as diffusion, growth or cell chemotaxis.
2.1.3 Cellular Automata
The Cellular Automata (CA) approach to modelling biological systems is a power-
ful tool for modelling both temporal and spatiotemporal processes. In CA models
the environment of the models is represented by a discrete lattice/grid where the
23
states of the components evolve synschronously in discrete time steps according to
a set of rules [23]. The CA simulation Conways Game of Life was one of the first
computer applications in biology [26]. This model consisted of randomly placed
cells on a square lattice and simulated birth, death and interactions according to
pairwise interaction rules which used Boolean logic conditions.
In basic CA models, the objects of the model do not strictly move, but rather
their properties or attributes are updated each time step, allowing movement to be
represented indirectly. A variation on this technique is the dynamic cellular au-
tomata (DCA) approach, which allows for the explicit modelling of movement and
is conceptually similar to the agent-based modelling approach [27]. Cellular au-
tomata approaches are particularly amenable to modelling stochastic spatial and
temporal processes such as transport processes, cell migration, diffusion or viral in-
fection. They can also be useful for visualising processes such as chemotaxis, drug
diffusion or pattern formation.
The robustness and adaptability of the cellular automata modelling approach has
made it amenable to simulating a wide range of biological process, from enzyme-
kinetics and hydrodynamics studies to the progression of HIV/AIDS [28, 29]. Cel-
lular automata theory has also been used successfully to explain pattern formation
in bacterial colonies [30].
2.1.4 Agent-Based Approach
An alternative approach to modelling bacterial growth and development is the
agent-based (or individual-based) modelling approach [31, 32]. The distinguishing
characteristic of the agent-based approach is that the properties of the individual
cells, rather than the colony as a whole, are modelled. This “bottom-up” approach
24
allows a finer-grained analysis, connecting local changes at the cellular level to the
overall patterns of population growth. The agent-based approach shares some of the
strengths of the cellular automata modelling approach, in that it is able to explicitly
model both temporal and spatiotemporal processes. For this reason, it is particularly
amenable to modelling processes such as chemotaxis, diffusion and pattern forma-
tion in bacterial colonies. However, it represents an even finer grained approach in
that the individual biological entities being modelled are explicitly represented by
unique software objects.
It must be noted that the agent-based approach and higher-level mathematical
approaches are not mutually exclusive but rather complement each other in studies
of population dynamics. The latter approach allows a general conceptual frame-
work to be developed for a population which can lead to theories at the systems
level. The agent-based approach meanwhile allows important features of the indi-
viduals to be taken into account and related to the overall system’s properties. The
agent-based approach can suffer from being more computationally intensive and de-
pendent on empirical data than high-level mathematical approaches such as ODEs
because each individual of a population is explicitly modelled. However, in cases
where the population being modelled expresses a high degree of heterogeneity, both
spatially and between individuals, the agent-based approach represents a powerful
tool for exploring how this heterogeneity contributes to the system dynamics.
The next section contains an overview of existing agent-based models that have
been used to explore bacterial population development. Following this, the Micro-
Gen Bacterial Simulator which was developed over the course of this Ph.D project
is introduced.
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2.2 Examples of Agent-Based Models of Bacteria
2.2.1 BacSim Model
One of the most significant examples of an agent-based (or individual-based) mod-
elling approach to modelling microbial colonies is the ‘BacSim’ simulator [32]. It
is an individual-based model that uses the known physiology of individual cells
to produce a quantitative model of microbial colony development. When it was
introduced, it differed from previous models of microbial colony growth which de-
pended on mathematical and cellular automaton approaches to address this problem
[33, 24, 30].
BacSim had an advantage over the previous approaches in that it explicitly al-
lowed for spatial differences in the environment and between the individual bacte-
rial cells. It demonstrated the power of this modelling technique for exploring the
heterogeneous population dynamics occurring within a microbial colony. For ex-
ample, it was used to explore the effects of growth asynchrony and random variation
of cell parameters on population development [32].
BacSim was further developed into a two-dimensional multi-substrate, multi-
species model of microbial biofilms [34]. Biofilms are multi-species communities
of surface-attached micro-organisms characterised by their genetic diversity, struc-
tural heterogeneity and complex cellular interactions. Although the model allowed
a continuous 3D space for bacterial movement, the extra dimension for bacterial
movement was restricted to about two cell diameters and the substrate diffusion-
reaction was restricted to 2D space, so therefore it was described as essentially a
2D model.
The model was compared to an established biomass-based model (BbM) of
biofilm growth where the spreading of biomass was dictated by cellular automata
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rules [35]. Biomass-based models are spatially structured population models where
the interactions of the biomass units lead to the emergent development of the
community. The comparison between the individual-based and biomass-based ap-
proaches showed qualitative agreement in terms of the overall growth of the simu-
lated biofilms. However, it must be noted that the study did not take into account
the different phenotypic characteristics of cells in biofilms or the complex three-
dimensional structure of biofilms.
BacSim has continued to be developed since then and used to address questions
such as the migration of Salmonella enteridis in hen’s eggs, and the population
dynamics during the lag phase of bacterial growth [36, 37, 38]. It was used as a
basis for studying cell division at the individual-level in order to understand better
the mechanistic principles underlying the lag phase. These different applications
of the agent-based modelling paradigm illustrate the power of this approach for
investigating many factors of microbial population development and connecting
them with information obtained at the cellular level.
2.2.2 INDISIM Model
Another important model developed to investigate microbial population dynamics
using an agent-based approach is INDISM, which stands for Individual Discrete
Simulations [31]. INDISIM differs from BacSim in that whereas the latter treated
bacterial cells in continuous space (with discrete time) INDISIM is discrete in both
space and time. However, they both share in common the fact that they represent
bacterial colonies with respect to their individual cells allowing for spatial hetero-
geneity in the environment and individual variability between the different cells.
INDISIM has been used to study biomass distributions, growth rates and metabolic
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oscillations in simulated batch culture bacterial colonies [31].
The environment of INDISIM is represented as a discrete grid with each lattice
point containing variables storing the concentrations of different types of particles,
for example nutrients, reaction products or residual products. The diffusion of par-
ticles through the environment is calculated using a discretized implementation of
Fick’s First Law of diffusion. Like BacSim, individual rules are applied to the bac-
terial cells for motion, uptake, metabolism, reproduction and viability.
Simulations with INIDISIM have shown that it can be used to reproduce quali-
tatively the growth patterns of Bacillus subtilis bacteria on an agar plate [39]. It was
also used in studies of the lag phase, where it was demonstrated that the evolution
of the mean mass and biomass distribution of a colony was a determining factor for
entering the exponential phase of bacterial growth and the rate of enzyme synthesis
also had a direct effect on lag duration [40, 41].
Finally, an extended version of INDISIM, INDISIM-SOM has been applied in
studies of the dynamics of soil organic matter (SOM) and the evolution of carbon
and nitrogen sources in the soil and their effect on microbial growth [42]. The agent-
based approach is particularly suitable for modelling an environment such as soil
since it is a heterogeneous, discontinuous environment with discrete microhabitats
where the chemical and biological properties vary greatly over small distances.
2.2.3 Other Agent-Based Bacterial Models
A number of different agent-based simulators were developed in the lab of R. Paton
to approach the problem of modelling bacterial cells. These were built on previous
work using the agent-based approach to model ecological systems involving learn-
ing herbivore animals in a world populated by plants [43]. The COSMIC system
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was an agent-based model of evolution in bacterial cells involving four levels of
interaction in the system (Environment - Individual Cells - Gene Products - Genes)
[44, 45]. The BacSim model, described above, was used for representing cell
growth and division. COSMIC introduced an extra level of complexity by incor-
porating a genetic component into the bacterial cells, and a parallel implementation
was created to take advantage of parallel computing resources.
COSMIC incorporated a gene transcription network that outputted a ‘flagella
activation protein’ which was a generic gene product responsible for bacterial
movement. This gene product triggered motility and chemotaxis towards areas
of higher nutrient concentration, creating a positive feedback loop for the gene
transcription network. The goal of COSMIC was to evolve a genome that max-
imised cell growth as a result of this feedback loop. Although COSMIC repre-
sented a somewhat limited implementation of a genetic component, it demonstrated
the strength of the agent-based modelling approach for investigating questions such
as the evolution of bacterial agents over time to produce different phenotypes that
affect cell survival.
A simpler model of bacterial growth, which did not include a gene component,
was also developed in the same laboratory, called RUBAM [44]. The bacterial
agents incorporated a Learning Classifier System (LCS) based on fuzzy logic for
implementing chemotaxis. The LCS was the decision making component of a feed-
back loop that included the environment, sensors to detect the environment and
directed swimming of the bacterial cell. This resulted in the evolution of survival
strategies from an initial pool of bacterial agents initialized with random rules. With
this approach it took a long time to find good solutions, but the bacteria would even-
tually evolve to a point where they could adapt to prevailing conditions and respond
to environmental stimuli.
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The most recent project from the lab of R. Paton, COSMIC-Rules, attempts to
combine the experiences from COSMIC and RUBAM to develop an agent-based
model consisting of three levels: the genome, bacterial cell, and environment [43].
Each individual bacterium has a unique location, size, state of cell division and
genome. The model expands on the genetic component of the original COSMIC
model to incorporate representations of plasmids and bacteriophages which add to
the complexity of the population dynamics. This means that horizontal transfer of
genetic information within a population can occur as well as vertical transmission
between generations.
The agent-based modelling approach has also been applied to understand the
mechanisms that affect microcolony and biofilm formation in bacteria by L.R. John-
son in the University of California [46]. A model was developed there to infer how
the patterns observed in the early stages of biofilm formation are affected by the be-
haviour of the individual bacterial cells. The formation of groups was modelled as a
function of the doubling rates, stopping rates and the strength of the interactions be-
tween the cells. This could be used to make predictions about how the inter-cellular
interactions affect the mean colony size and maximum colony size for example.
2.2.4 BAIT & Micro-Gen Bacterial Simulator
The ‘Micro-Gen Bacterial Simulator’ was developed to model the growth and in-
teractions of bacterial cells with antibiotics in vitro using the agent-based approach
[17, 18]. It was built on existing work in the laboratory to develop an agent-based
model of bacterial growth in culture called the Bacteria-Antibiotic Interaction Tool
(BAIT) [16]. BAIT incorporated a simple model of bacterial growth and inter-
actions with antibiotic molecules in a discrete two-dimensional grid environment
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using the Java programming language. Mathieu Joubert, as part of an internship
project in the laboratory, developed a C++ version of BAIT which formed the ba-
sis for the Micro-Gen project. Micro-Gen represents a significant expansion and
re-design of the original BAIT tool, in order to build a more realistic representation
of bacterial growth and development in culture and their kinetic interactions with
antibiotics.
The theory of autonomous agents is a useful approach for the modelling of
bacterial cell colonies as it allows large-scale population models to be derived from
simple rules dictating the growth and interactions of the individual bacterial cells
of the population. The Micro-Gen Bacterial Simulator uses information about the
cell biology of bacteria to produce global information about population growth in
different environmental conditions.
An agent-based approach was chosen over a simpler mass action model in or-
der to explicitly model the heterogeneity in environmental conditions, for example
between the interior and exterior of the colony, and between individual bacterial
cells. In complex microbial communities, such as biofilms, there can be highly
heterogeneous localised niches where the chemistry varies dramatically over small
distances.
A key component of the model is the ability to quantitatively model antibiotic
molecules and their interactions with the bacterial cells. These interactions are gov-
erned by defined kinetic parameters specific to the type of antibiotic and bacterial
strain being modelled. This allows a quantitative model of antibiotic interactions
with bacteria to be built up and their pharmacokinetic properties to be investigated.
The model also incorporates two important antibiotic resistance mechanisms
employed by bacterial cells against antimicrobial agents which form the cornerstone
of the antibiotic arsenal: special enzymes released by bacteria, called β-lactamases,
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which degrade the antibiotic molecules, and reduced binding affinities between the
antibiotics and receptors in the bacterial cells. These antibiotic resistance mecha-
nisms are of great clinical concern as their development and spread across many
species of bacteria has led to the erosion of the efficacy of many commonly pre-
scribed antibiotics, in particular penicillin and its derivatives. Moreover, the pro-
duction of these β-lactamases persists in multidrug resistant strains, which can be
resistant to more than ten different antibiotics.
2.3 Methicillin-Resistant Staphylococcus aureus
2.3.1 Overview
The emergence of multi-drug resistance in Staphylococcus aureus bacteria has be-
come a major healthcare problem in recent years. Prior to the introduction of antibi-
otics, patients with S. aureus bacteraemia had a mortality rate of over 80% [9]. This
situation improved dramatically when the first β-lactam antibiotic, penicillin, was
introduced into clinical use during the early 1940s [10]. However, the widespread
therapeutic use of penicillin resulted in selection for strains of S. aureus carrying
antibiotic resistance mechanisms [47]. By 1950, penicillin resistance was recorded
in over 50% of all staphylococcal isolates [48]. Today greater than 95% of all S. au-
reus isolates possess resistance to penicillin, and 40-60% of clinical isolates in the
United States of America and the United Kingdom express methicillin resistance
[11, 12].
Members of the Staphylococcus aureus species are gram-positive bacteria with
spherical-shaped cells (cocci) approximately 0.5 - 1µm in diameter [49]. They di-
vide in three planes, with a generation time of approximately 30 minutes, result-
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ing in three-dimensional, cuboidal packets of cells [49]. They are non-motile and
generally exist as part of the normal flora found on nasal passages, skin and mu-
cous membranes in humans. However, S. aureus strains have the potential to cause
a variety of infections from superficial skin lesions such as boils, to more seri-
ous conditions such as pneumonia. S. aureus is also a major cause of nosocomial
(hospital-acquired) and community-acquired infections [50, 51].
2.3.2 Antibiotic Resistance Mechanisms
Antibiotic resistance refers to the ability of a microorganism to resist the effects of
an antibiotic. The development and spread of antibiotic resistance in pathogenic
bacteria is affected by a complex range of interacting factors. The appearance of
resistant strains of bacteria is thought to be an ancient evolutionary event, however
the fitness cost associated with resistance mechanisms previously limited their pro-
liferation [52]. In recent years, the widespread use of antibiotics has resulted in a
significant positive selective pressure for resistant strains, particularly in the clinical
setting [11].
There are several responses that have been observed in bacteria in response to
selective pressure by the widespread use of β-lactam antibiotics. These include
the deletion of porin proteins in gram-negative bacteria to block the passage of an-
tibiotic molecules through the bacterium’s outer membrane, and also the activation
of efflux exporter proteins [53, 54]. However, perhaps the most important resis-
tance mechanisms in gram-positive pathogens such as S. aureus bacteria are the
expression of enzymes called β-lactamases, and alterations to the molecular targets
(Penicillin-Binding Proteins) of the antibiotics (see Fig. 2.2).
The mediator of penicillin resistance in S. aureus is a β-lactamase enzyme
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Figure 2.2: Schematic representation of main antibiotic resistance strategies in
MRSA bacteria. A. Expression of alternate form of PBP2, called PBP2a, with re-
duced binding affinity for antibiotic. B. Production of β-lactamase enzyme which
cleaves antibiotic molecules.
which hydrolytically cleaves the β-lactam ring present in penicillin and other β-
lactam antibiotics (Fig. 2.3). β-lactamase was first discovered in Escherichia coli
bacteria in 1940, and β-lactamase-expressing S. aureus bacteria were isolated soon
afterwards [55, 56, 47]. The appearance of β-lactamases is thought to be an ancient
evolutionary event. However their broadened distribution across many bacterial
species, under selective pressure from antibiotic usage, has become a serious health
concern [54].
Four variants of S. aureus β-lactamase have been identified by immunologic
methods (types A-D) [19]. The most well studied β-lactamase is the class A β-
lactamase characteristic of S. aureus strain PC1 [58]. This is encoded by the blaZ
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Figure 2.3: Examples of the chemical structures of three common β-lactam an-
tibiotics: A. Penicillin G. B. Ampicillin. C. Cephalothin. They are characterised
by the presence of a β-lactam ring structure (square at the centre of each structure
above). Chemical structures were derived from the on-line DrugBank cheminfor-
matics database [57].
gene which is carried on a transposable element of a large plasmid. Expression of
β-lactamase is regulated by the interaction between β-lactams in the environment
and a cell surface signal-transducer protein BlaR1 [48, 59]. After induction of ex-
pression, most of the β-lactamase enzyme is secreted into the extracellular milieu,
while some remains bound to the cytoplasmic membrane of the cell [60]. When the
antibiotic concentration in the environment decreases, re-repression of β-lactamase
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expression occurs because BlaR1 is no longer auto-activated [61]. A study by Nor-
ris et al. (1994) found that among 50 β-lactamase-producing MRSA isolates taken
from nine locations across the U.S.A., 80% expressed type A β-lactamase and the
remainder expressed type C. Type B and type D β-lactamases are thought to be less
common among MRSA strains [1].
Despite fifty years of selective pressure from continued use of β-lactam an-
tibiotics, S. aureus has not acquired any new or modified β-lactamases [48]. This
differs considerably from other species, such as Escherichia coli where over a hun-
dred TEM β-lactamase variants have arisen from the ancestral TEM-1 gene [62].
However, some S. aureus strains have developed another mechanism that confers
resistance to β-lactam drugs, including methicillin. This is based on alterations to
the penicillin-binding proteins, which are the main molecular targets of β-lactam
antibiotics in bacteria.
The introduction of methicillin in 1959 to treat infections of penicillin-resistant
Staphylococcus aureus resulted in the selection of MRSA strains [48]. As early
as 1961, MRSA strains were isolated and there has been a steady increase in inci-
dences since then [63]. Normal S. aureus cells produce four types of membrane-
bound transpeptidase proteins called penicillin-binding proteins (PBPs 1-4), which
assemble and regulate the final stages of cell wall biosynthesis. The mode of ac-
tion of the β-lactam antibiotics involves the acylation of a catalytic residue in the
transpeptidase active site of PBPs which results in the inhibition of the correspond-
ing catalytic activity (cell-wall cross-linking). However, MRSA bacteria contain a
gene called mecA, which encodes an extra penicillin-binding protein, PBP2a.
The mecA gene is located on the staphylococcal cassette chromosome mec
(SCCmec), which is a mobile genetic element capable of transferral across dif-
ferent bacterial species [64]. At present, there are five known types of SCCmec
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(types I - V) distinguished by their genetic composition and size [65]. It is not
known at what frequency SCCmec is acquired in nature, however Robinson & En-
right estimated that methicillin resistance in S. aureus may have been acquired on
over 20 separate occasions during evolutionary history, with SCCmec Type IV the
most frequently acquired [66]. SCCmec Type IV has been associated with a recent
increase in community-acquired MRSA. This may be due to its smaller size and
lower fitness cost compared to the SCCmec types I-III [67].
The product of the mecA gene, PBP2a, does not bind the β-lactam moiety read-
ily because the approach to the active site is sterically encumbered. When an MRSA
organism is subjected to β-lactam stress, PBP2a confers resistance by supplement-
ing its transpeptidase activity (cell-wall cross-linking) to the transglycosylase func-
tion of native PBPs during cell wall synthesis [48].
2.3.3 Pharmacokinetics and Pharmacodynamics
The term pharmacokinetics refers to the absorption, distribution and decay of drugs
in patients, which determines the time course of drug concentrations in serum [68].
The complementary field of pharmacodynamics, in the context of antibiotic thera-
pies, deals with investigating the functional relationship between the concentration
of drug and the rate of growth/death of the bacteria in its presence [69]. The most
common pharmacodynamic parameter used in the clinical setting has traditionally
been the minimum inhibitory concentration (MIC) of a drug. This is the concentra-
tion of antibiotic that ensures a net rate of bacterial growth equal to zero. However,
this parameter on its own does not give insights into the time course of antimicrobial
activity, or persistent effects of the drugs such as the post-antibiotic effect (PAE),
which is the length of time that bacterial growth continues to be inhibited after re-
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moval of the antibiotic [68]. For this reason, in recent decades there has been exten-
sive research into developing detailed pharmacokinetic-pharmacodynamic models
that can be used to optimize treatment regimens of antimicrobial drugs and aid in
rational drug design strategies.
The pharmacodynamics of antibiotics are usually studied in vitro by develop-
ing time-kill curves of exponentially growing bacteria exposed to different concen-
trations of antibiotics [69]. Pharmacodynamic functions are a means of formally
describing the relationship between bacterial growth/death and the antibiotic con-
centration. This functional description can range from a very simple form, like
the MIC, to more complex mathematical models such as the sigmoid Emax mod-
els which quantitatively describe the net growth rate of the bacterial colony as a
function of the antibiotic concentration [69].
The sigmoid Emax model is a highly flexible, non-linear model which is used to
capture many concentration-effect relationships. It takes into account a minimum
threshold drug concentration below which little or no effect is observed, a log-linear
drug concentration versus effect intensity relationship, and a plateau at relatively
high drug concentrations [70]. Simpler models of the concentration-effect relation-
ship, such as linear or log-linear models, have been used when data are available
over a limited effect intensity range [71]. However, the Emax model is more com-
monly used because it can take into account the leveling of drug effect at higher
drug concentrations and appears to be more physiologically relevant [70].
Mechanism-based mathematical pharmacokinetic-pharmacodynamic (PK-PD)
models generally incorporate equations or sub-models describing microbial growth,
the effects of the antimicrobial drugs, and the changing drug concentrations. A
recent review by Czock & Keller (2007) showed that most published mathematical
mechanism-based PK-PD models can be derived from a common model of anti-
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microbial drug effects based on cell growth and cell killing processes [72]. In this
common model, two pharmacodynamic functions are incorporated which determine
the replication and death rates of the bacterial colony respectively in relation to the
drug concentration. The relationship between the rate of bacterial growth inhibition
and the drug concentration is described using a sigmoid Emax model. The second
pharmacodynamic equation, which relates the increase in the rate of bacterial death
to drug concentration, is also based on a sigmoid Emax model. This commonality
among the apparently different models allowed their parameters to be related to the
MIC and to a common set of PK-PD indices [72].
Even the most inclusive pharmacodynamics functions assume a global (popu-
lation based) killing function that changes according to the changes in antibiotic
concentration. However, the approach followed in the current work documented in
this thesis involves the explicit incorporation of the kinetics of the interaction be-
tween antibiotics and the macromolecules involved in resistance and derives from
it those concentrations of antibiotic that lead to inhibition of bacterial growth. This
approach is complementary to the pharmacokinetic-pharmacodynamic modelling
approach generally used to assess and model drug efficacy. It approaches the un-
derstanding of drug function and efficacy from the perspective of the underlying
biochemical mechanisms that lead to the observed outcome. This, in conjunction
with PK-PD studies, would allow a computational framework of analysis for relat-
ing molecular/biochemical data with more high level pharmacological studies.
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CHAPTER 3
MODEL DESCRIPTION
3.1 Overview
The Micro-Gen Bacterial Simulator is an extended and modified version of an
agent-based Java software tool called BAIT (Bacteria-Antibiotic Interaction Tool)
[16]. Micro-Gen is coded in the C++ object oriented programming language. The
individual microorganisms are represented by software agents which store physical
traits of the bacterial cells as well as behavioural rules associated with them. The
modular nature of the program means that functionalities/characteristics specific to
particular bacterial species can be readily incorporated into the basic cellular model.
This research describes work carried out to simulate the antibiotic resistance mech-
anisms specific to MRSA bacteria. However, to illustrate the capacity of Micro-Gen
to simulate various bacterial populations, some test results simulating Escherichia
coli are also included to demonstrate the effect of motility on bacterial behaviour.
3.1.1 Environment
The culture environment is represented by a discrete, two-dimensional grid contain-
ing diffusible elements such as nutrients (glucose), enzymes and antibiotics. Each
40
discrete grid position (called a “patch”) in the environment contains variables to
record the levels of nutrients, antibiotics and bacterial enzymes in it. It also in-
cludes pointers to bacterial agents that currently occupy the patch. The movement
of molecules in the environment is assumed to occur according to the process of
random diffusion down local concentration gradients. A discretized implementa-
tion of Fick’s first law of diffusion is used to calculate the movement of molecules
between adjacent patches [31]. According to the diffusion algorithm, the amount
of substance exchanged between two adjacent patches is proportional to the con-
centration difference (∆Mol) multiplied by a user-defined diffusion coefficient, D
(Fig. 3.1A). The diffusion coefficient determines the proportion of molecules that
are exchanged between two patches during each time step. When patches are diag-
onally adjacent to one another a diffusion rate modifier (1/√2) is applied.
There is also another higher-level diffusion rate modifier to take into account the
relative differences in the molecular mass (Mr) of the various molecules (glucose,
antibiotics, β-lactamases). The rate modifier of glucose is 1.0, i.e. the user-defined
diffusion co-efficient D directly determines the rate of diffusion of glucose. The
rates of diffusion of the other molecules are expressed relative to glucose. Glucose
was chosen as the benchmark since it is the smallest molecule that is simulated
in the model. The diffusion rate modifiers for the other molecules are calculated
by dividing the Mr of glucose by the Mr of the diffusing molecule. The rate of
diffusion is not influenced by the density of bacterial cells in the current patch, but
this will be included in future work to develop a more detailed model of particle
diffusion within a colony.
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Figure 3.1: A. Diffusion algorthim applied to molecules. D = diffusion coefficient,
∆Mol = concentration difference. B. Overcrowding algorithm applied to bacterial
cells. p(xi) = probability of bacterial agent moving to patch i; [bio]i = bacterial
biomass in patch i.
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3.2 Principal Model Entities
3.2.1 Bacterial Agents
The bacterial agents have a number of parameters associated with them along with
a set of behavioural rules that dictate how they interact with the environment. The
agents are an abstract representation of bacterial cells with the internal subcellular
processes not explicitly modelled. This is done in order to minimize the number
of parameters associated with each agent, because of the principle that each new
parameter makes it more difficult to understand what a model does [13]. The agent-
based approach can result in more parameter-rich models than with mathematical
state variable modelling, but this problem can be alleviated somewhat by the aggre-
gation of details into a single parameter. However, it is a challenge to determine the
appropriate level of aggregation since there is often a trade-off between ‘realism’
and keeping the model as simple as possible. The main input parameters for the
bacterial agents are listed in Table 3.1.
The bacterial software agents are stored in a “fabric” (array) data structure
which is initialized with a pool of bacterial agents at the start of the simulation.
Bacterial agents in the fabric only become active in the simulation when they are
flagged as “alive”. When reproduction occurs and a new daughter agent is added
to the environment, one of the non-active agents in the fabric is switched to ac-
tive status and its variables updated. The pre-initialization of a pool of non-active
agents in a fabric at the start of the simulation means that new software objects do
not have to be created or destroyed in memory every time a bacterium is born or
dies. This results in significant performance gains when dealing with large popula-
tions of agents. Furthermore, algorithms are used to maintain the bacterial fabric in
a non-fragmented state with active agents stored in contiguous blocks of memory.
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This is done to minimize the memory access times which otherwise could lead to a
significant performance bottleneck when running large numbers of agents.
Table 3.1: Input Parameters for Bacterial Agents in Micro-Gen model. Sample
values for S. aureus species included. b.u. = biomass units
Input Parameter Input Value
Biomass threshold for division 10000
Nutrient Intake (b.u. loop−1) 10.0
Survival cost (b.u. loop−1) 0.2
Stationary phase relative metabolic rate 0.2
Lag phase length (min) 66
β-lactamase production rate (µM s−1) 3.28 x 10−7
β-lactamase production cost (b.u.) 0.1
Antibiotic Intake (µM) 6.0 x 10−8
Kinetic Parameters (k2, Kd, kcat, KM ), see Table 3.2
3.2.1.1 Growth Parameters
The biomass of the cell is tracked within the simulation by using simulation units
called “biomass units”. Bacterial agents increase their biomass by absorbing nutri-
ent from the immediate environment. The rate of nutrient absorption is determined
by the “nutrient intake” parameter specified by the user. There is also a “survival
cost” associated with normal metabolic activities of the cell and this is subtracted
from the cell biomass each time step. As the agent accumulates nutrient, its biomass
increases until it reaches a certain threshold (“biomass threshold for division”) when
reproduction is triggered. Bacterial cells reproduce asexually by the process of bi-
nary fission, whereby a cell divides into two identical daughters cells approximately
half the size of the original cell.
The nutrient intake rate and biomass threshold for division were determined
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by fitting to an experimentally determined bacterial doubling time of 29 minutes,
which is the estimated generation time of S. aureus strain BB255 [73]. The survival
cost parameter influences the length of the stationary phase of the growth cycle.
A higher survival cost results in a shorter stationary phase because cells enter the
death phase more quickly. A survival cost of 2% of the rate of nutrient intake
was chosen for the test simulations recorded here. This represents a level which
does not limit the exponential phase of bacterial growth (see Chapter 4). However,
in nature this would vary considerably between different strains and for a more
detailed quantitative representation of the growth curve of a particular strain this
would need to be estimated from experimental studies.
Some other parameters associated with the bacterial agents are the “stationary
phase relative metabolic rate” and the “lag phase length”. The first parameter refers
to a state of reduced metabolic activity that bacterial cells enter when they are sub-
jected to severe stress such as nutrient deprivation. The “survival cost” parameter
is multiplied by the proportion specified. The principal effect of this parameter is
to modify the length of the stationary phase (see Chapter 4). It represents the bac-
terium’s ability to preserve itself in hostile, nutrient-deprived conditions by shutting
down non-essential metabolic activities. A sample value of 0.2 is used in our test
simulations for illustrative purposes, however as with the “survival cost” parame-
ter, this would need to be experimentally estimated in order to give a quantitatively
accurate representation of the length of the stationary phase. It is not a signifi-
cant factor in the simulations for predicting the Minimum Inhibitory Concentration
(MIC) of an antibiotic (Chapter 5) since the drug is added during the exponential
phase of growth prior to the bacteria entering the stationary phase.
The “lag phase length” parameter specifies the length of time it takes for the
bacteria to adapt to their new environment at the start of the simulation. During this
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phase, bacterial cells synthesise the required cellular components to adapt to their
conditions. Their rate of nutrient intake increases from an initial low level until
the maximum intake rate is achieved. This represents the accumulation of proteins
required to process the nutrients available in the bacterium’s new environment. The
underlying dynamics that determine the length of the lag phase are not explicitly
modelled, however there is a random element introduced by the fact that the bacteria
are initialized with different energy states at the start of the simulation. Prats et
al. (2008) describe a more detailed model of the underlying population dynamics
occurring within the lag phase using an agent-based approach [41].
3.2.1.2 Antibiotic Resistance Mechanisms
If the bacteria are exposed to antibiotics, this triggers the synthesis and release of an
enzyme called β-lactamase into the extracellular milieu (Fig. 3.2). The β-lactamase
enzyme is an important defensive protein that bacterial cells secrete to destroy any
β-lactam antibiotics (e.g penicillin) in their vicinity. The rate of β-lactamase pro-
duction and the extra metabolic cost associated with it can be specified by the user.
For our simulations, the β-lactamase production rate was estimated by varying it
over a range of values and calculating the minimum inhibitory concentration (MIC)
of penicillin G at each value (using kinetic parameters for penicillin G described
below). The β-lactamase production rate was chosen as that which resulted in a
simulated MIC equal to the experimentally determined MIC for penicillin G versus
the particular bacterial strain being modelled.
For the test simulations, Type A and Type C β-lactamase-producing MRSA
strains were modelled and calibrated with the experimental results of Nor-
ris et al. (1993) for penicillin G (Type A MIC = 72.1µg/ml; Type C =
47.9µg/ml) [1]. Based on this, the β-lactamase production rates were es-
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Figure 3.2: Schematic representation of release of β-lactamase enzymes from S.
aureus cell. Production of β-lactamase is induced by binding of β-lactam antibi-
otics to a cell surface signal transducer protein (BlaR1). Most of the β-lactamase
enzyme is secreted into the extracellular milieu while some remains bound to the
cytoplasmic membrane of the cell.
timated to be 3.28 x 10−7 µM s−1 agent−1 for the type A simulated strain and
1.62 x 10−7 µM s−1 agent−1 for the type C simulated strain.
There are a number of parameters listed in Table 1 dealing with the interactions
between the bacterial agent and antibiotic molecules. The antibiotic intake parame-
ter determines the rate at which free antibiotic is depleted in the patch by absorption
across the cell wall of the bacteria. There are two kinetic parameters (k2, Kd) which
determine the rate at which the antibiotic molecules bind to penicillin-binding pro-
teins (PBPs) in the cytoplasmic membrane, underneath the cell wall. There are also
two kinetic parameters (kcat, KM ) that describe the interactions between antibiotic
molecules and β-lactamase enzymes in the environment. Values for these kinetic
parameters were taken directly from experimental literature and are explained in
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the sections on antibiotics and β-lactamases below.
3.2.1.3 Movement and Chemotaxis
The bacterial agents in Micro-Gen, for motile bacteria, can implement a “run and
tumble” mode of movement characteristic of species with flagella, such as Es-
cherichia coli [74]. They move forward smoothly during the “run” phases and
reorient to a random direction during the alternating “tumble” phases (Fig. 3.3).
They also display positive chemotaxis when exposed to nutrient concentration gra-
dients. This is facilitated by a temporal sensing system whereby the bacteria peri-
odically compare nutrient concentrations as they move from patch to patch through
the environment [75]. When a bacterium encounters a positive nutrient gradient it
lengthens the time of its “run” phase, and the relative duration of runs and tumbles
determines if the cell moves towards or away from a chemical environment.
The impact of positive chemotaxis by the bacterial agents in the presence of nu-
trient gradients is illustrated in Figure 3.4. The bacteria possess a temporal sensing
system to detect nutrient gradients and move towards areas of higher nutrient con-
centration. In Figure 3.4, two localised areas with higher nutrient concentrations
were created in the upper-left and lower-right corners of the environment. As the
nutrient diffuses into the rest of the environment it produces a gradient and the bac-
teria respond by moving up this gradient. In Figure 3.4D (taken at the 2 hour time
point), the bacterial cells, marked in yellow, can be seen clustered around the areas
of high nutrient concentration, represented by lighter shades of grey.
3.2.1.4 Overcrowding Algorithm
In the case of S. aureus bacteria, which are non-motile, an overcrowding algorithm
is applied to take into account the physical size constraints of a single patch in
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Tumble
Run
E. coli cell
Flagellum
Figure 3.3: Diagram of “run and tumble” mode of movement characteristic of bac-
teria with flagella (e.g. E. coli). During the run phase, bacteria swim forward by
active propulsion from the flagellum. This is punctuated by tumbles, where the cell
randomly reorients to a new direction. Decreased frequency of tumbles in response
to a chemical attractant gradient (e.g. nutrient) results in migration of the cell up
the gradient in an analogous way to a biased random walk (chemotaxis).
the environment. The area of each patch is configured to represent approximately
1µm2 of medium. Depending on the size of the bacterial species being simulated,
overcrowding will come into effect when more bacteria occupy the patch than can
be accommodated. For example, the estimated cell diameter of a newly divided S.
aureus cell is 0.5µm [49]. Therefore, when more than four such cells occupy a
single patch an overcrowding algorithm is applied (Fig. 3.1B). According to this,
the probability, p(xi), of a bacterial cell in an overcrowded patch being moved to
an adjacent patch i is inversely proportional to the relative bacterial biomass in the
adjacent patch. The direction a cell is moved is determined by sampling from the
resultant probability distribution of the surrounding patches.
A ‘bacOvercrowd’ input parameter may be specified by the user to control the
rate of spreading of the bacterial colony across the surface of the environment. If
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A. (Time = 2 min) B. (Time = 33min)
C. (Time = 1 hour) D. (Time = 2 hours)
Figure 3.4: Screenshots from Micro-Gen illustrating positive chemotaxis of motile
bacterial agents towards areas of higher nutrient concentration: (A) Bacteria (yel-
low) initially randomly distributed, with localised areas of high nutrient concentra-
tion initialised in upper-left and lower-right corners of the environment. (B - D) As
nutrient diffuses into the environment, the bacteria detect the nutrient concentration
gradient and move towards areas of higher nutrient concentration. Nutrient lev-
els in environment are represented by colour-coded gradient (lighter shade = higher
conc.) with blue, green and red colours representing high, medium and low nutrient
concentrations, respectively.
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the bacterial biomass in the current patch is greater than bacOvercrowd multiplied
by the lowest bacterial biomass in an adjacent patch then the bacterial overcrowding
algorithm is applied. For example, with a bacOvercrowd value of 1.0 there must
be at least one adjacent patch with a bacterial biomass less than or equal to the
current patch for there to be a chance of a bacterial cell being moved. On the other
hand with a value of 2.0, the bacterial biomass must be twice the level of all the
surrounding patches. A higher value results in more densely packed cells and less
radial expansion of the colony (Fig. 3.5).
The bacOvercrowd parameter may be thought of as a crude “aggregation” con-
straint. However, a more sophisticated model of cell aggregation would need to
be implemented to recreate the complex cell assemblages found, for example, in
biofilm communities. However, the bacterial overcrowding algorithm suffices to
represent the gradual spreading of non-motile S. aureus cells across the surface of
an agar plate. The parameter is used to ensure that movement of bacterial cells is
always down a bacterial biomass concentration gradient (bacOvercrowd> 1.0). In-
creasing the bacOvercrowd input value affects the transition from the exponential to
the stationary phases of the bacterial population growth curve (Fig. 3.6). For the test
simulations documented in this report, a bacOvercrowd value of 1.3 was used. This
represents a relatively unconstrained expansion of the colony (down the bacterial
biomass concentration gradient), i.e. only minimal cell aggregation is assumed.
3.2.2 Antibiotics
The quantities of antibiotics in the environment are stored as variables in each patch
and subject to diffusion as described above. Each molecule has a distinct half-
life derived from the biological literature which determines its rate of degradation
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A. B.
C. D.
Figure 3.5: Effect of ‘bacOvercrowd’ parameter on the radial expansion of bac-
terial colonies. Four different simulations were carried out with different input
values for bacOvercrowd: A. bacOvercrowd = 1.0; B. bacOvercrowd = 1.3; C. ba-
cOvercrowd = 1.6; D. bacOvercrowd = 2.0. Higher values of bacOvercrowd result
in more aggregation of bacterial cells and less radial expansion. Images were pro-
duced using the open-source ‘Animp’ 3D visualisation software (developed by Ray
Seyfarth, University of Southern Mississippi, USA).
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Figure 3.6: Log growth curves of simulated MRSA bacterial agents grown under
in vitro culture conditions with different ‘bacOvercrowd’ input parameter values
(1.0 - 2.0) Initial inoculum = 64 bacterial agents.
over time (Table 5.3) [57]. If there are bacterial agents in the patch they will
absorb antibiotic according to their specified rate of intake. The ability of β-lactam
antibiotics to inhibit bacterial cell division is based on the fact that they bind to
proteins in the cell membrane called penicillin-binding proteins (PBP) which are
necessary for cell division (Fig. 3.7). Upon binding to PBP the antibiotic inactivates
it and if a significant proportion of PBPs in the cell are inactivated the bacteria will
be unable to reproduce and cell death may occur [49].
The interactions between the β-lactam antibiotic molecules and PBP2a are ex-
plicitly represented in the simulation. However, the interactions with the other PBPs
present in the bacterial cell membrane (PBPs 1 - 4) are not explicitly modelled for
the MRSA bacterial agents. This is sufficient for representing MRSA because the
limiting reaction for antibiotic efficacy is that with PBP2a, which has a binding
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Antibiotic
PBP = Penicillin-Binding Protein
PBP PBP
Acylated 
(inactive)
Active
Figure 3.7: Schematic representation of β-lactam antibiotic (e.g. penicillin or
cephalothin) binding to penicillin-binding protein (PBP) in cell membrane of bacte-
rial cell. PBP is required for normal cell wall synthesis to occur during cell division.
However, binding and acylation of the PBP by antibiotic results in inhibition of this
function.
affinity for β-lactams that is reduced compared to the other PBPs. This reduces
the level of complexity caused by introducing more empirical parameters into the
model.
There is an internal counter associated with each bacterial agent which repre-
sents the proportion of PBP2a molecules that have been acylated (or bound) by
antibiotics. When this value reaches 100%, then death of the bacterial agent occurs.
Reproduction will only occur successfully when the percentage of bound PBP2a in
the bacterial agent is<10%. When the percentage of bound PBP2a is between 10%
and 100%, cell division is assumed to be disrupted until normal turnover of protein
in the cell reduces this percentage below the threshold again. The threshold values
are maintained constant across all the simulations documented here in order to be
able to compare the relative efficacies of the antibiotics against a single hypotheti-
cal MRSA strain. In nature, however, the relative values for these thresholds might
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vary considerably between different strains [76].
In order to quantify the efficacy of the antibiotic at inhibiting cell division, ki-
netic parameters describing the reaction between antibiotic and PBP2a in the cell
are used. This is a pre-steady state reaction, with the parameters k2 (rate of inacti-
vation of PBP2a), and Kd (dissociation constant) used to describe it. The ratio of
these values (k2/Kd), or the second order rate constant, is a convenient measure of
the antibiotic efficacy at inhibiting PBP2a function. The proportion of PBP2a that
is inactivated per second, ka (the apparent first order rate constant), at a given drug
concentration can be calculated as a function of these parameters (equation 3.1)
[76].
ka =
k2[Ab]
Kd + [Ab]
(3.1)
Values for the kinetic parameters, k2 and Kd, of PBP2a were derived from the
biological literature (Table 3.2) [77, 78, 20]. By inputting these parameters it was
possible to estimate the proportion of PBP2a de-activated by antibiotic each time
step. Once the proportion of acylated PBP2a crosses a certain threshold, then cell
division is inhibited (see above).
3.2.3 β-lactamase Enzymes
β-lactamase enzymes are proteins produced by resistant bacteria that attack a com-
mon type of antibiotic, called β-lactams, which includes penicillins, such as peni-
cillin G and ampicillin, and cephalosporins such as cephalothin. In the case of
MRSA bacteria, most of the enzyme is released into the extracellular milieu where
it binds to and cleaves antibiotic molecules (Fig. 2.2B).
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When a β-lactamase-producing bacterium comes into contact with antibiotic,
an intracellular signal is sent to activate expression of the β-lactamase gene. A
true/false flag for β-lactamase expression is associated with each bacterial agent.
After the first interaction (when the flag is changed to true), there is an exponential
increase in the β-lactamase production rate until the maximum rate is reached after
approximately eighty minutes [59]. This corresponds to the activation of gene ex-
pression mediated by antibiotic binding to the signal-transducer protein BlaR1, as
described in chapter 3.
β-lactamase is released into the local patch where it is subject to diffusion ac-
cording to Fick’s First law of diffusion, as described above. It also has a defined
half-life parameter determining its rate of degradation over time in the environ-
ment. When antibiotic has been removed from the environment, re-repression of
β-lactamase expression occurs (BlaR1 is no longer auto-activated - software flag
changed to false).
The interactions between β-lactamase enzymes and antibiotic molecules in the
same patch are governed by defined kinetic rules. Michaelis-Menten kinetics are
used to describe the reaction, with the reaction rate, V, calculated as the rate at
which antibiotic is cleaved (or de-activated) by the enzyme (equation 3.2):
V =
kcat[E]t[Ab]
KM + [Ab]
(3.2)
The kinetic parameters required as input to the model are the turnover rate,
kcat, and the Michaelis constant, KM , the ratio of which (kcat/KM ) is often used
as a measure of enzyme efficiency [19]. These were derived from the biological
literature for MRSA (Table 3.2) [19]. [E]t and [Ab] refer to the concentrations of
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Table 3.2: Kinetic Parameters of β-lactam Antibiotics versus Type A and Type C
β-lactamase-producing MRSA. Pen G = Penicillin G; Amp = Ampicillin; Ceph =
Cephalothin.
Parameter
Type A MRSA Type C MRSA
Pen G Amp Ceph Pen G Amp Ceph
kcat (s−1) 171.0 308.0 0.015 210.0 355.0 0.095
KM (µM) 51.1 255.0 6.8 55.9 122.0 5.2
k2 (s−1) 0.185 0.0047 0.00115 0.185 0.0047 0.00115
Kd (µM) 15400 495 586 15400 495 586
β-lactamase enzyme (sum of both free and occupied enzyme) and antibiotic in the
local patch respectively.
3.2.4 Pro-Drugs
The basic premise of the enzyme-catalysed therapeutic activation (ECTA) pro-drug
treatment strategy is that a substrate-like pro-drug molecule containing a β-lactam
structure is administered to treat an infection. When it comes into contact with
β-lactamase producing bacteria, it undergoes therapeutic activation by cleavage of
its β-lactam ring which causes selective release of a cytotoxic anti-microbial agent
[79, 80]. More details about this approach are included in chapter 6.
From a conceptual standpoint, the pro-drugs are represented as antimicrobial
agents that start the simulation in an inactive form, but become flagged to ‘active’
status when they come into contact with β-lactamase enzymes in the environment.
The reaction between pro-drug and β-lactamase is defined by the same reaction
kinetics that were used to represent the antibiotic-β-lactamase reaction (equation
3.2). This is because it is essentially the same reaction between a β-lactam ring
structure in the pro-drug molecule and the β-lactamase enzyme. However, the out-
come of the interaction is reversed, whereby the pro-drug molecule is activated
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after cleavage of its β-lactam ring structure, rather than inactivated as is the case
with traditional antibiotic molecules.
The active component of a pro-drug may be any type of antimicrobial agent
depending on how it was designed. Therefore, in order to represent specific pro-
drugs, the Micro-Gen model would have to be adapted to take into account the
specific mode of action of the particular active agent released. For the purposes
of this study, the aim was to assess the pro-drug delivery system from a general
perspective so the emphasis was placed on analysing the effects of the β-lactamase
mediated activation step.
For the case study described in chapter 6, the active component of the pro-drugs
NB2001 and NB2030 was triclosan. The mode of action of this drug is not fully
understood, although it is thought that an important component is the binding to
the enoyl-[acyl-carrier-protein] reductase (FabI) enzyme involved in the bacterial
fatty acid synthesis cycle [81]. The interaction between the activated component of
the pro-drug and the bacterial cell was modelled using the pre-steady state reaction
kinetics described above for the β-lactam antibiotics (equation 3.1).
3.3 Program Structure
3.3.1 Program Flow Structure
Micro-Gen is coded in the C++ object-oriented programming language with indi-
vidual components of the simulation represented by software objects. At the start
of a simulation, the main components of the environment, the patches, are initial-
ized, along with the bacterial fabric containing the pool of pre-initialized bacterial
agents.
58
The principle activities of the simulation are carried out during the main pro-
gram loop which represents a discrete time step of the model (Fig. 3.8). The loop
is configured to represent approximately two seconds of real-time, although this is
modifiable by the user to apply a different temporal granularity. The various time-
dependent input parameters (e.g. nutrient intake rate, antibiotic kinetic parameters)
must be configured to the specified timescale.
The program loop is divided into six distinct steps during which different as-
pects of the simulation are implemented. The first step (diffusion) is to update the
levels of the various molecular constituents (nutrients, antibiotics and enzymes) of
the environment. Fick’s first law of diffusion is applied at this point to model the
movement of free molecules between patches.
Step two (metabolism) is when the basic metabolic processes of the bacterial
cells are modelled. This includes subtracting a survival cost from the bacterium’s
energy stock, representing energy expended on basic housekeeping duties in the
cell. If β-lactamase gene expression is active then the enzyme is produced and
secreted into the environment, with an associated energy cost.
The third step is to update the positions of the bacterial agents by applying a
movement algorithm. In the case of bacteria capable of propelled locomotion, such
as Escherichia coli, the model implements their characteristic “run and tumble”
motion [17]. E. coli cells can respond to a chemical stimulus (chemotaxis) such as
a positive nutrient gradient by extending the length of their run phase relative to the
tumble phase. This results in movement of the cells towards regions of higher nutri-
ent content. S. aureus cells are immotile so there is no active movement algorithm
associated with them. However, if a patch becomes overcrowded then it is possi-
ble for cells to be shunted into an adjacent patch, in which case an overcrowding
algorithm is applied at this step (Fig. 3.1B).
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Figure 3.8: Diagram of program flow structure in Micro-Gen Bacterial Simulator,
including the main stages of program loop.
Step 4 (agent interactions) of the program loop is when the kinetic rules for
bacteria-antibiotic and β-lactamase-antibiotic interactions are applied. These re-
actions are governed by defined kinetic rules, with parameters derived from bio-
chemical studies used to determine the reaction rates (Eqs. 3.1, 3.2). During the
following step (feeding), the bacterial agents take up nutrient from the environment
at a defined rate. In the case of the simulations carried out for this study, the rate is
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that which will result in a generation time of 29 minutes [73].
The final stage of the loop is when bacterial agents reproduce according to the
process of binary fission, producing two identical daughter cells. Reproduction is
dependent on the fact that the bacterial cell’s energy store has exceeded a defined
threshold for replication, and the level of antibiotic damage (proportion of inacti-
vated PBP) is below a critical level. The exit conditions for the simulation are if
there are no longer any bacterial agents alive or a specified number of loops have
been completed.
3.3.2 Graphical Output
The simulation may be run with an optional dynamic graphical display that shows
the positions of bacteria in the environment and the levels of various molecular com-
ponents such as nutrients or antibiotics in real-time. This can be useful for studying
pattern formation in colonies. For example, in Figure 3.9, the characteristic circular
colonies of S. aureus bacteria can be seen.
The model also outputs a movie file compatible with the open-source 3D visual-
isation software ‘Animp’ (Animated Particles) developed by Ray Seyfarth (Univer-
sity of Southern Mississippi, Hattiesburg, MS 39406, USA). Animp is an OpenGL-
based 3D renderer that takes advantage of modern 3D graphics cards for visualising
particles in three-dimensional space. Although Micro-Gen is a two dimensional
model (X and Y dimensions), it produces a pseudo-3D output (for visualisation
purposes) by assigning the Z dimension to represent the number of bacterial cells
in a patch (Fig. 3.10). This 3D visualisation is useful, for example, for assessing
the effect of the bacterial overcrowding algorithm on cell densities within a colony
(Fig. 3.5). However, it will become more important when Micro-Gen is expanded to
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Figure 3.9: Screenshot of Micro-Gen simulation showing growing S. aureus
colonies (yellow-brown, lighter = higher bacterial biomass) on simulated nutrient
agar medium. Shaded blue contours represent nutrient gradient (lighter blue =
higher nutrient concentration).
represent three-dimensional space, which is an important future aim of the project.
3.3.3 Parallelisation
A challenge of modelling from the individual cellular level up is that it requires
a significant amount of computing resources in order to scale up to biologically
realistic numbers of cells. For example, the concentration of bacterial cells in na-
ture can range from 106 - 1010 cells per millilitre of seawater [82]. Despite rapid
advances in traditional desktop computers, due to their memory and performance
limitations it is currently not practically feasible to model the numbers of agents
typically found in nature using only a single processor. Therefore, it is important
to be able to take advantage of parallel high performance computing resources in
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Figure 3.10: Screenshot of Animp 3D movie file generated by Micro-Gen simula-
tion showing growing S. aureus colonies (yellow spheres). Images were produced
using the open-source ‘Animp’ 3D visualisation software (developed by Ray Sey-
farth, University of Southern Mississippi, USA).
order to tackle problem at a more realistic scale.
Micro-Gen is designed to take advantage of high performance computing re-
sources by incorporating an implementation of the Message Passing Interface (MPI)
for running in parallel on multiple computers. The strategy of domain decompo-
sition is used for parallelisation, whereby the simulation environment is divided
equally among the computing nodes (Fig. 3.12). Each node processes its section of
the environment independently of the other nodes. Communication between adja-
cent nodes occurs at overlapping boundary conditions where quantities such as nu-
trient, antibiotic and enzyme levels are exchanged during each time step (Fig. 3.13).
For example, when a bacterial cell crosses over the border separating parts of the
environment controlled by two different processors/computers then the bacterium
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Figure 3.11: Diagram of principal classes of Micro-Gen model using standard UML
notation. Yellow shaded components represent base classes of a generalised agent-
based model. Derived classes specific to Micro-Gen, which contain functionality
for representing bacterial cells and antibiotics, are shaded in blue-green.
is sent across to the other computer in an analogous way to sending a letter between
two postal addresses.
By being able to run the simulation in tandem across multiple proces-
sors/computers, it frees up the traditional limitations of computing resources found
in the desktop space. The model can be scaled up to as many processors/computers
as there are available in order to increase the environment size from the microscopic
level up to a visible scale. However, it is important to optimize parallel algorithms
to avoid the process of diminishing returns as the numbers of processors are in-
creased. This is because with more processors there is more traffic/communication
between them and this can result in significant bottlenecks.
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Figure 3.12: Screenshot of Micro-Gen simulation running in parallel on four com-
puting nodes, with bacterial colonies (yellow) growing on nutrient agar medium
(blue). Lighter shade of blue represents higher nutrient concentration, and lighter
shade of yellow represent higher bacterial biomass in patch.
For this reason, particular emphasis has been placed on optimizing the commu-
nication strategy for sending bacterial agents between different computer nodes in
Micro-Gen, while ensuring the integrity of the information in transit. At each iter-
ation of the main program loop, data of the same type that has to be transferred be-
tween nodes is collected into communication buffers and then sent as a single large
message, rather than a series of smaller individual messages in order to minimize
the latencies associated with multiple message calls. Advances in communication
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Figure 3.13: Schematic representation of communication between adjacent nodes
when Micro-Gen is run in a parallel configuration. Overlapping boundary condi-
tions are shaded.
technology for connecting computer nodes within clusters have also minimized the
overheads associated with communication traffic.
The movement of bacteria between nodes is complicated by the fact that MPI
has no in-built mechanisms for communicating software objects between nodes.
Therefore, the constituent cell traits of the bacterial agents are communicated as
basic variables. When these variables are received, pre-initialized bacterial agents
from the fabric data structure are used to make a copy of the bacteria on the receiv-
ing node. The availability of a pool of pre-initialized bacterial agents minimizes
the performance penalty associated with this step, since new bacterial objects do
not have to be created/destroyed in memory each time a bacterial agent is sent to a
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new node. This means that a simulation can be seamlessly divided among multiple
processors/computers to obtain an efficient speed-up on parallel architectures.
3.3.3.1 Parallel Performance
It is important to be able to scale up the simulation to represent biologically realis-
tic numbers of agents in order to correctly predict emergent population behaviour.
The model is scalable to represent population sizes of >107 bacterial agents, so as
to represent more closely the numbers found in nature. For example, when simu-
lating the standard growth curve of a bacterial population with a maximum size of
0.5 x 107 bacteria (environment size = 10002 patches) it takes 158 minutes to simu-
late 33 hours of real-time on a local 16 x2.8 GHz Pentium 4 computing cluster (Dell
PowerEdge 1750), with the total memory footprint of the program across all nodes
<512 MB. The parallel efficiency of the algorithm was found to be >90% when
tested in parallel across the 16 nodes (Table 3.3) [18].
Table 3.3: Parallel Efficiency of Micro-Gen When Run on a 16 Node (Intel Xeon
2.8 GHz) Computing Cluster
No. of Nodes Parallel Efficiency (%)
4 97.6
9 97.2
16 91.1
The communication overheads associated with sending agents between nodes
are minimized by the use of the ‘fabric’ data structure containing a pool of pre-
initialized bacterial agents (see above). A defragmentation routine is applied to the
bacterial fabric to prevent efficiency losses accumulating as agents are interchanged
between nodes. Without this defragmentation step, the overall execution time would
increase by over four-fold for the test conditions above due to gradual fragmentation
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of the fabric data structure.
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CHAPTER 4
POPULATION DYNAMICS
4.1 Overview
Micro-Gen is a highly scalable, parallel model that can be used to test theoreti-
cal assumptions about bacterial cell biology and how it affects overall population
dynamics. A number of test simulations were carried out to explore the mechanis-
tic basis of the model and how changes in the input parameters affect the model
output. This involved testing situations or parameter values that may not occur in
nature (so-called ‘strong cues’) in order to gain insight into the mechanisms im-
portant for the model output. Examining extreme or hypothetical scenarios is an
important step in developing an agent-based model, due to its inherent complexity,
in order to understand how the model works and identify potential limitations [13].
4.2 System Dynamics
For the test simulations, the effect of one parameter was investigated while all other
parameters were kept constant in order to isolate the influence of the particular
parameter under investigation. For the same reason, the test simulations involved
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a phenotypically homogeneous bacterial population growing in a heterogeneous
environment. This is to avoid any ambiguity in the output resulting from random
factors related to different competing sub-populations. However, the strength of
the agent-based approach exists in being able to easily introduce this heterogeneity
into the model in order to study more complex situations, which will be the topic of
future work.
The strain of bacteria modelled in these simulations was MRSA, a clinically
important pathogenic strain (see Chap. 3). The dimensions of the environment were
1000 x 1000 patches or grid elements (approximately 1mm2 in real-world) with
each patch containing 80000 simulation units (called “biomass units”) of nutrient.
Biomass units are used to express the amount of nutrient available relative to the
bacterial nutrient intake rate (10 b.u. loop−1).
4.2.1 Standard Bacterial Growth Curve
Populations of bacteria follow a standard growth curve consisting of lag, log, sta-
tionary and death phases, when grown in nutrient limited culture conditions. During
the initial lag phase, there is no net increase in cell numbers as the cells adapt to
their new conditions. The log phase is when the bacterial numbers increase ex-
ponentially until nutrient or space constraints limit their growth and they enter the
stationary phase. The final death phase occurs when the available nutrient reserves
have been exhausted. This behaviour is reproduced in the model by incorporating
five key parameters: lag phase length; nutrient intake rate/biomass threshold for
division; survival cost; and relative stationary phase metabolic rate (see Chap. 3).
The lag phase is the initial period after inoculation in fresh culture medium
when cell division has not begun to occur [83]. During this phase, the bacteria
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begin to synthesize macromolecules required to transport and process the nutrients
from their new environment. Once they have adapted to their environment, cell
division begins to occur and the bacteria enter the logarithmic phase of growth.
This is typified by an exponential rate of increase in cell numbers until nutrient
availability or accumulation of waste products begins to limit growth.
When the nutrient content of the medium has been exhausted, the bacteria typ-
ically enter the stationary phase where no net increase/decrease in cell numbers is
observed. Bacteria in this phase are characterised by a metabolically less active and
more resistant state [84, 85]. A low level of endogenous metabolism is maintained
and the rate of protein turnover by the cell increases. However, as nutrient starva-
tion persists, eventually most of the cells enter the death phase, characterised by an
exponential decrease in viable cell counts.
The length of the lag phase is influenced by the energy state of the cells when
they are added to the environment and the lag phase length parameter. Each cell
is randomly set with a particular energy state (in biomass units) at the start of the
simulation. The maximum rate of growth during the exponential phase is deter-
mined by the nutrient intake rate relative to the biomass threshold for division (see
Chap. 3). The effect of the survival cost parameter can be seen in Figure 4.1A by
varying over a range of 1 - 64% (relative to nutrient intake rate), i.e. with a value
of 1%, the bacterial cell burns up approximately 1% of the nutrient it absorbs in
normal metabolic activities per loop. A survival cost input value of 8% or more
results in no apparent stationary phase for the simulated population as a whole, but
instead the population immediately enters the death phase following the exponen-
tial phase. Also, the relative stationary phase metabolic rate parameter is important
for determining the length of the stationary phase (Fig. 4.1B). However, it has no
influence on the exponential phase or entry into the stationary phase.
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Figure 4.1: Log growth curves of simulated MRSA bacterial agents grown under
simulated in vitro culture conditions with different input values for: (A) “Survival
Cost” parameter (1% - 64%) - values represented as a percentage of the bacterial
nutrient intake rate (10.0 b.u. loop−1 - see Chap. 3); (B) “Stationary Phase Rela-
tive Metabolic Rate” (0.01 - 1.0) - representing the relative survival cost during the
stationary phase when the bacterial cells enter a state of reduced metabolic activity
induced by severe stress such as nutrient deprivation.
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4.2.2 Antibiotic Intake Rate
Figure 4.5 shows results from varying the antibiotic intake rates for penicillin G,
ampicillin and cephalothin on the length of time bacterial growth is inhibited by the
antibiotics. The antibiotic intake rate is proportional to the amount of PBP proteins
in the cell membrane of S. aureus. As this parameter is increased, more antibiotic
is bound per time step, thus depleting the available reserve in the local environment
more quickly. A range of values was explored in order to assess the impact of this
parameter on the model.
The intake rate parameter was varied in the range 10−10 to 10−5 µM loop−1 to
investigate how this influences the output of the simulation. For cephalothin, the
rate of antibiotic intake does not have any significant effect on the inhibition time
of the drug over the wide range of values tested. For penicillin G and ampicillin,
the antibiotic intake rate directly influences the inhibition time up to a certain point.
However, interestingly, in the range 10−8 - 10−5 there is no significant change in the
inhibition times. Therefore, there seems to be an upper limit (10−8), in the context
of this model, above which a higher number of PBPs in the cell membrane does not
affect the efficacy of the antibiotics.
For all further test simulations, an antibiotic intake rate of 6.0 x 10−8 was chosen
which represents a comparatively high number of PBP proteins in the cell mem-
brane. This was chosen in order to represent the worst case scenario in terms of
drug treatment success, i.e. an MRSA bacterial cell that expresses a high number of
PBP proteins will be inherently more resistant to β-lactam antibiotics. However, fu-
ture work will include expanding the model to include a more detailed quantitative
representation of the interactions of the antibiotic molecules not only with PBP2a,
but also with the other PBPs (1 - 4) characteristic of S. aureus bacteria, using exper-
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imentally estimated data about the total number of PBP copies per cell [86]. Then a
better quantitative estimation of the antibiotic intake rate would be able to be made.
4.2.3 Antibiotic Half-Life
In order to explore the effects of antibiotic half-life on the outcome of treatment of
MRSA, this parameter was varied over a range of 5 minutes to 8 hours for the an-
tibiotics penicillin G and cephalothin (Fig. 4.2). These two antibiotics were chosen
in order to illustrate the different responses that can occur to changes in half-life
depending on the type of antibiotic used. Cephalothin is predicted to be strongly
sensitive to changes in half-life. For example, increasing the half-life from 30 min-
utes to 480 minutes results in a ten-fold increase in the length of time MRSA growth
is inhibited by the antibiotic. However, for penicillin a similar change in half-life
results in less than a 10% increase in inhibition time.
The half-life of an antibiotic can be an important determinant of treatment suc-
cess. It varies considerable depending on environmental conditions, and in partic-
ular the half-life of an antibiotic in vivo (i.e. in a patient) is often considerably
reduced compared to in vitro laboratory conditions. Therefore, it is useful to un-
derstand the impact of the half-life parameter on our predicted results for antibiotic
efficacy.
It is interesting to note from the results that penicillin G is not as sensitive to
half-life changes as cephalothin is. A possible explanation for this is that it is due
to the different reaction profiles of cephalothin and penicillin G with MRSA. As
will be discussed further in the next chapter, cephalothin is relatively resistant to
β-lactamase enzymes (low kcat/KM ) secreted by the MRSA bacteria. Cephalothin
binds slowly to penicillin-binding protein 2a (PBP 2a) in the bacterial cell mem-
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Figure 4.2: Predicted effect of half-life parameter of antibiotic molecules on length
of time bacterial growth is inhibited. Antibiotic added after 4.4 hours of simulated
time, during exponential phase of growth. Cephalothin = 103.1µg/ml; Penicillin
G = 72.1µg/ml. Round points represent default input values for half-life parameters
(Ceph,= 30 min; Pen G = 42 min) [57].
brane, and increasing the half-life directly improves efficacy by allowing more
antibiotic to survive for a longer time to bind to the MRSA. Penicillin G on the
other hand is cleaved more rapidly by β-lactamase enzymes in the environment and
therefore, increasing its half-life does not improve the efficacy since it is rapidly
destroyed by the β-lactamases.
4.2.4 Diffusion Rate
In order to investigate the effects of nutrient availability on the growth and develop-
ment of bacterial colonies the user-defined diffusion coefficient for Fick’s First Law
of diffusion was varied over the range 0.0 - 0.2, where a larger co-efficient means
a higher rate of diffusion (Fig. 4.3). The rate of diffusion is an important param-
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Figure 4.3: Effect of rate of diffusion on log growth curves of simulated MRSA
bacterial agents grown under simulated in vitro culture conditions. The diffusion
co-efficient for Fick’s First Law of diffusion was varied between 0.0 - 0.2. The
characteristic phases of the standard bacterial growth curve (lag, log, stationary and
death phases) are observable. Environment size = 10002 patches. Cellular input
parameters listed in Chapter 3.
eter dictating population development as it limits the transfer of nutrients towards
the interior of a bacterial colony. The diffusion co-efficient for Fick’s First Law of
diffusion may be configured to represent different environments by calibrating with
experimental results. However, for the tests here the aim was to give a more gener-
alised assessment of the mechanistic influences of the diffusion algorithm on model
output. It must be noted that the diffusion algorithm applies to molecular move-
ment between patches, not within a patch. Each discrete patch, or grid element, is
assumed to have a homogeneous concentration of molecules.
As can be seen in figure 4.3, in the absence of diffusion (rate = 0.0) the bac-
terial growth curve still follows the four standard stages expected under in vitro
culture conditions. However, the maximum population size is severely limited due
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to the lack of nutrient transport between patches. This could explain why bacterial
colonies tend to thrive better in conditions of water availability where nutrients are
more readily transported by diffusion. In arid conditions, the lack of nutrient diffu-
sion would be a significant growth-limiting factor, aside from problems associated
with dessication.
When a trace amount of diffusion (rate = 0.001) is applied, the maximum bac-
terial population size increases by 2 - 3 orders of magnitude over conditions where
diffusion is absent. However, as the diffusion rate is increased the maximum bacte-
rial population size is limited by the total nutrient content (carrying capacity of the
environment). Higher diffusion rates result in the population peaking in a shorter
time, but the carrying capacity remains similar. It can be concluded from this that
environments with high rates of diffusion do not confer an advantage to bacterial
colonies in terms of the overall population sizes they support. However, these con-
ditions may allow the colony to gain a foothold more quickly allowing a critical
mass to be developed which is more resistant to external stresses.
When antibiotic is added to the bacterial cultures, the rate of diffusion in the
environment can have a significant impact on the efficacy of the antibiotic. To in-
vestigate this, the length of time bacterial growth was inhibited (which is a measure
of antibiotic efficacy) was recorded over the range of diffusion co-efficient values
0.001 - 0.2, using kinetic parameters for three common antibiotics: penicillin G,
ampicillin and cephalothin (Fig. 4.4). The results show a significant positive cor-
relation (Pen G: r> 0.992, p< 0.01; Amp: r = 0.993, p< 0.01) between the rate
of diffusion and the inhibition times for penicillin G and ampicillin. However, for
cephalothin the diffusion rate has no effect on the length of time growth is inhibited
(r = 0.0).
The effect of environmental conditions such as the rate of diffusion can have an
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Figure 4.4: Effect of varying diffusion co-efficient of Fick’s First Law of diffusion
(0.001 - 0.2) on the length of time bacterial growth is inhibited after addition of
antibiotic to the environment. The antibiotic was added (time = 4.4 hours) during
the exponential phase of growth of a population of Type A β-lactamase-producing
MRSA. Population size = ∼105 agents; environment size = 10002 patches. The
concentration of each antibiotic was: penicillin G (Pen) = 66.9 µg/ml, ampicillin
(Amp) = 69.9 µg/ml, and cephalothin (Ceph) = 118.9 µg/ml. Cellular and kinetic
input parameters listed in Chapter 3.
important impact on antibiotic treatment outcome. For example, it has been found
that some bacteria can form structured communities of cells such as biofilms, where
the rate of diffusion within the colony is significantly reduced [87]. The results
from this computational analysis clearly indicate that a decreased rate of diffusion
can result in reduced antibiotic efficacy, depending on the type of antibiotic, and
therefore increase the bacteria’s survival chances.
Cephalothin, which is unaffected by variations in the diffusion rate, differs from
penicillin G and ampicillin in that it is a poor substrate for the β-lactamase enzyme
produced by MRSA bacteria. Penicillin G and ampicillin are both rapidly cleaved
by β-lactamase enzymes secreted into the immediate environment of the bacterial
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cells, and the diffusion rate limits the rate at which the antibiotic is replenished.
For cephalothin, it is more resistant to cleavage by β-lactamase enzyme and as a
result the local concentration of antibiotic does not decrease significantly. Instead,
the factor that limits the efficacy of cephalothin is the rate of binding to the bac-
terial cells, which is not influenced by the diffusion rate. This situation indicates
how the specific biochemical profile of the antibiotic and its interactions with lo-
cal environmental factors can have a significant impact on its reaction to changing
environmental conditions.
Knowledge of how antibiotics react under different conditions could inform
the rational development of drug treatment regimens. For example, when treat-
ing bacterial infections where there is poor transport of antibiotic by diffusion (e.g.
biofilms), the model indicates that the susceptibility of the antibiotic to β-lactamase
plays a larger role than under normal free-diffusing conditions. This may result in
deviations between the expected behaviour as determined from laboratory experi-
ments and the actual real-world outcome.
4.2.5 Population Size (Inoculum Effect)
The Minimum Inhibitory Concentration (MIC) of an antibiotic is defined as the
minimum concentration of an antibiotic required to inhibit growth of a bacterial cul-
ture in vitro. Micro-Gen has been used previously to predict the MICs of antibiotics
by inputting relevant kinetic parameters for them [18, 88]. The present manuscript
provides a detailed overview of the model structure and parameters used to describe
the bacterial cells and focuses on the effects of changing environmental conditions
and population size on the development of an MRSA colony.
The MIC is an emergent property of the population that results from the in-
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teractions of the individual bacterial agents and antibiotics. However, it is some-
times difficult to relate information from cellular and molecular studies with this
high-level population parameter. The Micro-Gen model provides a good theoreti-
cal framework for bridging this gap of knowledge between fundamental studies at
the individual level and high-level population parameters such as the MIC.
Figure 4.6 shows results from simulations investigating the effect of population
size (inoculum effect) on the MICs of a number of common β-lactam antibotics
against MRSA. Three types of MRSA bacteria were tested: Type-A (Fig. 4.6A)
and Type-C (Fig. 4.6B) β-lactamase producing strains, and a β-lactamase-negative
strain (control). The strains are differentiated by their unique kinetic parameters
and β-lactamase production rates (see Chap. 3). The β-lactamase production rates
were estimated as described in chapter 3, and the antibiotic intake rate was chosen
as described above. The diffusion rate for the environment was set to 0.1 to ensure
that bacterial growth was not diffusion-limited (see Fig. 4.3).
When the population size is varied by several orders of magnitude the results
indicate that the β-lactamase status of the bacterial cells is an important contributor
to the inoculum effect on the MIC (Fig. 4.6A, B). There is no clear inoculum effect
associated with cephalothin against either Type-A or Type-C β-lactamase produc-
ing MRSA strains over the range of population sizes tested. This is consistent with
the fact that cephalothin is a poor substrate for either type of β-lactamase. In the
case of larger population sizes, the total concentration of β-lactamase available to
bind and de-activate antibiotic is increased. However, since cephalothin is a poor
substrate for the β-lactamase, the increased enzyme concentration does not have
a significant impact on the MIC. Rather the binding reaction between cephalothin
and PBP2a in the cell membrane of MRSA is the limiting factor for cephalothin’s
efficacy. It binds poorly to PBP2a, relative to penicillin G and ampicillin, which
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results in a high MIC that remains unchanged over the range of population sizes
tested.
Penicillin G and ampicillin are better substrates for cleavage by β-lactamase
enzyme. As a result, the MIC increases in response to higher concentrations of
enzyme in the environment. So even though penicillin G is shown to be more
effective than cephalothin at low population sizes, in the case of larger sizes (>106
bacterial agents) the advantage is negated. Experimental studies of various strains
of β-lactamase producing S. aureus have also shown a significantly larger inoculum
effect for penicillin G compared to cephalothin [89, 90].
The variation in the MIC of an antibiotic with different bacterial population
sizes is an important factor to consider when determining drug treatment regimens.
The stage of development of a bacterial infection and the number of bacteria present
at any given time can vary from patient to patient and over the course of a treatment
course. Therefore, it is useful to be able to quantify the impact of these changes on
the response of bacterial colonies to treatment.
4.2.6 β-lactamase Production Rate
Another important parameter that influences the MIC of a β-lactam drug is the β-
lactamase production rate. This can vary by several orders of magnitude between
different strains of MRSA. Therefore, it is important to assess the impact of this
parameter on model output. In order to do this, simulations were carried out over
a range of production rate values in order to illustrate the different effects it has
depending on the type of drug used (Fig. 4.7).
The results clearly show that for antibiotics that are sensitive to cleavage by β-
lactamase, such as penicillin G and ampicillin, there is a strong positive correlation
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between the enzyme production rate and the MIC of the drug (Pen G: r = 0.999,
p< 0.01; Amp: r = 0.998, p< 0.01). On the other hand, cephalothin, which is rela-
tively resistant to cleavage by the enzymes has no correlation between its MIC and
the β-lactamase production rate (r = 0.0). A more detailed discussion about the ef-
fects of the kinetic parameters on cleavage of antibiotics molecules by β-lactamase
is presented in the next chapter.
4.3 Conclusions
These initial results indicate that the emergent effects from the population dynamics
can have a dramatic impact on the efficacy of antibiotics. This must be taken into
account in the rational development of drug treatment regimens, as differences in
environmental conditions and bacterial phenotypes may result in varied responses
between individual patients. Micro-Gen provides a good theoretical framework for
investigating these effects in the context of a simulated environment. The agent-
based modelling approach can be used to understand the relationships and complex
sets of interactions taking place between the individual components of the system
and how they contribute to the high-level population dynamics. The value of the
model in making quantitative predictions depends on the availability of good ex-
perimental data about individual bacterial cells. However, it can also be used as
tool for developing a better mechanistic understanding of population dynamics by
varying key parameters and observing how they determine the model output.
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Figure 4.5: Effect of antibiotic intake rate on log growth curves of simulated MRSA
bacterial agents grown under simulated in vitro culture conditions. The antibiotic
intake rate was varied over the range 10−10 - 10−5 µM loop−1 to examine its impact
on the length of time bacterial growth is inhibited by the antibiotic. 71.9µg/ml
of Penicillin G (A), 62.9µg/ml of Ampicillin (B) or 119µg/ml of Cephalothin (C)
were added after 4.4 hours of growth, when the simulated bacterial colonies were
in the exponential phase of growth.
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Figure 4.6: The effect of the bacterial population size (“inoculum effect”) on
the Minimum Inhibitory Concentrations (MICs) of penicillin G (Pen), ampicillin
(Amp) and cephalothin (Ceph) against MRSA. Antibiotic was added (time = 4.4
hours) during the exponential phase of bacterial growth, and environment size was
12002 patches. Results from β-lactamase-negative MRSA (no lac) included as con-
trol. Cellular and kinetic input parameters are listed in Chapter 3. (A) Type A
β-lactamase-producing MRSA. (B) Type C β-lactamase-producing MRSA.
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Figure 4.7: Predicted Minimum Inhibitory Concentrations (M.I.C.) for penicillin
G, ampicillin and cephalothin from Micro-Gen model over a range of different β-
lactamase production rates for Type A (A) and Type C (B) β-lactamase-producing
MRSA bacteria. This data was used to estimate the β-lactamase production rate for
each bacterial strain by cross-referencing with the experimentally determined MICs
of penicillin G (Type A MRSA = 72.1 µg/ml, Type C MRSA = 47.9 µg/ml) [1].
85
CHAPTER 5
KINETIC STUDIES
5.1 Overview
This chapter documents the results of integrating antibiotic resistance mechanisms
into the bacterial agents, representing MRSA, and analyzing the system dynamics
of their interactions with some common β-lactam antibiotics. The aim of these
tests is to quantify the effects of the principal pharmacokinetic parameters of β-
lactam antibiotics on treatment outcome, and assess their impact in terms of some
common high-level measures of antibiotic efficacy such as the minimum inhibitory
concentration (MIC).
The complex relationship between the kinetics of drugs and emergent pharma-
codynamic parameters, such as the MIC, is an important area to explore for the
rational development of drug treatment regimens [69]. This provides a basis for
understanding the dynamics involved in the development of antibiotic resistance,
and help to develop strategies to limit its expansion. Micro-Gen represents a good
theoretical framework for analysing the in vitro dynamics of antibiotics interacting
with bacteria, though further work could involve extending the model to represent
the more complex dynamics found in the in vivo clinical setting.
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A set of input parameters, summarized in Table 5.3, are configured to represent
the attributes of the bacterial agents and the culture environment. For this study,
the model was configured to represent MRSA bacteria growing in agar plate cul-
ture. Parameters applicable to three types of MRSA bacteria were used, which are
differentiated by their β-lactamase status: type A MRSA and type C MRSA are
named because they produce β-lactamase enzymes of these respective types. A
β-lactamase-negative strain was also included.
Type A and Type C β-lactamase enzymes are distinguished by their kinetic pa-
rameters (kcat/KM ) which are derived from experimental literature (see Table 5.3).
They were chosen for this study because they are the most common types of β-
lactamase found in MRSA bacteria. A study by Norris et al. (1994) found that
among 50 β-lactamase-producing MRSA isolates taken from nine locations across
the U.S.A., 80% expressed type A β-lactamase and the remainder expressed type
C. Type B and type D β-lactamases are thought to be less common among MRSA
strains [1].
5.2 Minimum Inhibitory Concentration
5.2.1 Overview
Figure 5.1 shows the simulated growth curve of an MRSA bacterial colony in
Micro-Gen. The effect of adding an inhibitory dose (103.1 µg/ml) of cephalothin
antibiotic after 3.5 hours of incubation on the growth curve is also shown. The
control culture of MRSA, where no antibiotic is added, displays the characteris-
tic standard growth curve of bacteria grown in nutrient-limited culture conditions
(see chapter 4). The addition of antibiotic during the exponential phase of growth
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Figure 5.1: Effect of antibiotic exposure on simulated log growth curve of MRSA
bacteria in nutrient-limited culture conditions. Cephalothin antibiotic (103.1 µg/ml)
added after 3.5 hours of incubation, during the exponential phase of colony growth.
This results in inhibition of colony growth for a period of time (inhibition time) until
depletion of antibiotic according to its natural half-life, or hydrolysis by enzymes
such as β-lactamases, allows growth to resume.
causes inhibition of growth for a limited period of time. The length of time bacterial
growth is inhibited is important as it determines the recommended dosage regimen
for an antibiotic. It is affected by factors such as the half-life of the antibiotic, and
the action of bacterial enzymes, such as β-lactamases, which degrade the antibiotic
molecules.
The Minimum Inhibitory Concentration (MIC) was calculated from the model
for a number of common β-lactam antibiotics against MRSA, and compared with
real-world results. The MICs are estimated from the model in an analogous way
to the broth dilution test carried out in the experimental environment: a series of
simulations are carried out with varying concentrations of antibiotic applied. The
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minimum concentration of antibiotic that results in complete inhibition of bacterial
growth for a pre-determined length of time is recorded as the MIC.
Prior to carrying out a simulation to predict the antibiotic MIC against a specific
strain of bacteria, the β-lactamase production rate per second per bacterial agent
must first be estimated by calibrating with a known MIC of an antibiotic (in this
case penicillin G was used for calibration). The process involves predicting the
MIC of penicillin G from the model over a range of β-lactamase production rates.
The production rate that gives an MIC equivalent to the experimentally determined
value for penicillin G (in this case Type A MRSA = 72.1 µg/ml, Type C MRSA
= 47.9 µg/ml) is then used in all future simulations for that particular strain [1].
The β-lactamase production rate must be estimated on a strain by strain basis due
to potential significant variation between strains. For this study, the estimated β-
lactamase production rate for Type A MRSA was 3.28 x 10−7 µM s−1 per bacterial
agent and for Type C it was estimated to be 1.62 x 10−7 µM s−1 per agent.
5.2.2 Predicted MICs
Figure 5.2 contains the predicted MIC values for a number of common antibiotics
compared with results from experimental studies published in the scientific litera-
ture (table 5.1) [2, 1]. The MICs of the antibiotics were calculated for three differ-
ent types of MRSA bacteria: β-lactamase producing strains (Type A, Type C), and
a β-lactamase negative strain. All other parameters, including the PBP2a kinetic
parameters, were maintained constant across the three types of bacteria. Overall,
there is a good correspondence between the predicted values from Micro-Gen and
the real-world situation.
The most notable deviation between the predicted and experimentally deter-
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Figure 5.2: Predicted versus experimentally determined geometric mean
MIC±SEM (µg/ml) of penicillin G, ampicillin and cephalothin antibiotics against
three different types of MRSA. Experimentally determined MICs for β-lactamase-
positive (Type A and C) strains are from Norris et al. (1994). Experimentally
determined MICs for β-lactamase-negative strains are from Malouin et al. (2003).
Predicted MICs are derived from triplicate simulations with the geometric mean
MIC±SEM (µg/ml) displayed. Where SEM = 0, no error bar is displayed. (A)
= Type A β-lactamase producing MRSA; (C) = Type C β-lactamase producing
MRSA; (-) = β-lactamase-negative MRSA.
mined MIC values is when comparing the results for ampicillin antibiotic against
Type A β-lactamase producing bacteria (53.5±2.3 µg/ml versus 89.3±17.0 µg/ml,
respectively). This may be due to intra-species variation in the kinetic parameters
for MRSA or differences in experimental methods for obtaining these values. The
second order rate constant for the PBP2a-ampicillin reaction (9.0 M−1 s−1) used
in the model was derived from experimental tests by Graves-Woodward & Pratt
(1998). However, another study by Fuda et al. (2004) has calculated the value to be
5.0 M−1 s−1 for ampicillin. When the rate constant from Fuda et al. for ampicillin
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Table 5.1: Results from comparison of predicted versus experimentally determined
MICs of penicillin G, ampicillin and cephalothin antibiotics (Ab) against three dif-
ferent types of MRSA. Geometric mean MIC±SEM (µg/ml) given. Experimen-
tally determined MICs are from Norris et al. (1994) and Malouin et al. (2003)
[1, 2].
Ab Type A Type C No Lac
Pred Exp Pred Exp Pred Exp
PEN 68.3±2.2 72.1±7.5 48.0±2.7 47.9±5.7 9.2±0.0 16±0.0
AMP 52.4±3.2 89.3±17 51.6±4.7 50.5±6.2 9.6±0.0 16±0.0
CEPH 103.1±0.0 91.3±8.2 103.1±0.0 83.9±8.9 103.1±0.0 128±0.0
was used into the model instead, it outputted a predicted MIC of 96.0±3.9 µg/ml,
which is closer to that recorded by Norris (89.3±17.0 µg/ml).
Figure 5.3 show how the predicted MIC of an antibiotic depends greatly on the
experimental estimates of the low-level kinetic parameters. This illustrates how
variation in parameters at the molecular level can have a significant impact on over-
all treatment response. It is therefore important to obtain reliable, accurate esti-
mates of the pharmacokinetic parameters for the antibiotics and bacterial strains
being investigated, in order to make conclusions about the emergent dynamics of
the system. There also may be significant natural variation between bacterial iso-
lates recovered from different locations or under different conditions.
The second-order rate constants calculated by Graves-Woodward & Pratt (1998)
were chosen over Fuda et al. (2004) because rate constants for all three antibiotics
used in this study were available, while Fuda’s paper did not contain kinetic values
for penicillin or cephalothin. Due to variation in experimental techniques between
different studies it is important to obtain parameter estimates from a single source
for consistency.
Figure 5.4 contains the results from a broader analysis of the MICs of a number
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Figure 5.3: Comparison of predicted MICs of ampicillin using kinetic parameters
derived from a study by Graves-Woodward & Pratt (1998) or a study by Fuda et
al. (2004). Experimentally determined MICs are from Norris et al. (1994) and
Malouin et al. (2003). Predicted MICs are derived from triplicate simulations with
the geometric mean MIC± SEM (µg/ml) displayed. (A) = Type A β-lactamase-
producing MRSA; (C) = Type C β-lactamase producing MRSA; (-) = β-lactamase-
negative MRSA.
of antibiotics compared with experimental estimates of MICs from the biological
literature (table 5.2) [1 - 8]. For these antibiotics, kinetic parameters were only
available for the PBP2a-antibiotic binding reaction and not for the β-lactamase re-
action. Therefore, only a β-lactamase-negative MRSA strain could be represented
in the simulations. Nonetheless, it is useful to be able to compare the predicted
MICs with those from the literature to assess the validity of the model across a
broader range of antibiotics.
The predicted MICs from Micro-Gen match closely the experimental MICs
across a wide selection of β-lactam antibiotics, comprising cephalosporins and
penicillins, including methicillin, and imipenem, a carbapenem (β-lactam) antibi-
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Figure 5.4: Comparison of predicted MICs and experimentally determined MICs
for eleven common β-lactam antibiotics versus β-lactamase-negative MRSA bac-
teria. The experimental values represent the arithmetic means (±SEM) of the min-
imum and maximum MIC values found in the literature [1 - 8]. Where SEM = 0, no
error bar is displayed.
otic. There is some degree of natural variation in the experimentally estimated
MICs, particularly for the cephalosporins, but overall there is a clear trend in the
data that matches closely with the predictions from Micro-Gen. The experimen-
tal MICs were chosen from strains of MRSA that were shown to be β-lactamase-
negative or where a β-lactamase inhibitor had been administered in conjunction
with the antibiotic.
5.2.3 Discussion
The results indicate that the model represents a robust tool for predicting the MIC
of an antibiotic against various different strains of bacteria based on low-level bio-
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Table 5.2: Results from comparison of predicted MICs and experimentally deter-
mined MICs for eleven common β-lactam antibiotics versus β-lactamase-negative
MRSA bacteria. The minimum and maximum MIC values found in a review of a
subset of the experimental literature are recorded [1, 2, 3, 4, 5, 6, 7, 8].
Antibiotic Predicted Exp MIC
MIC Min Max
Cefotaxime 506 256 512
Cefepime 151 4 128
Ceftazidime 117 128 256
Cephalothin 103 64 128
Cefoxitin 75.7 32 256
Cephaloridine 29.6 16 64
Penicillin 9.2 16 16
Ampicillin 9.61 16 16
Oxacillin 22.9 8 64
Imipenem 32.1 32 32
Methicillin 204 250 250
chemical/kinetic data about the antibiotic [77, 78, 20, 19]. Some degree of variation
from the experimental results is to be expected due to differences in the methods
and conditions used in the experimental studies to calculate the MICs and the ki-
netic parameters for the bacteria. Also, it must be noted that the experimental results
were derived from cultures grown suspended in three-dimensional liquid medium,
whereas Micro-Gen represents cultures growing in two-dimensional space. This
may also contribute to some of the variation between the predicted and experimen-
tally determined results.
Nevertheless, taking these factors into account, the high degree of correspon-
dence between the predicted and experimental MIC results is encouraging. These
results were obtained without attempting to ‘fit’ the kinetic input parameters to the
MIC results. The only parameter, which influences the kinetics of the bacterial
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agents, that required to be fitted was the β-lactamase production rate. However,
the results in figure 5.4 represent a β-lactamase-negative strain, and thus the fit-
ting step did not have to be carried out in this case. Therefore, the predicted MICs
were purely an emergent property of the inputted kinetic parameters for the PBP2a-
antibiotic binding reaction. There was still a close quantitative agreement between
the experimental and simulation results even in this scenario.
The Minimum Inhibitory Concentration (MIC) of an antibiotic is a common
high-level measurement for assessing and comparing the efficacies of different an-
tibiotics during the rational development of treatment regimens. These results in-
dicate that a global parameter (MIC) for a bacterial colony can be successfully
predicted by inputting parameters at the cellular/molecular level. This affords a dif-
ferent perspective on the factors that lead to a particular MIC being associated with
an antibiotic against a specific strain of bacteria. The MIC can be de-constructed to
investigate the contributions of different cellular parameters on it.
It must also be noted that the method for calculating the MICs of antibiotics
experimentally is limited in its precision compared to computational predictions.
For example, the experimental MICs derived from Norris et al. (1994) were calcu-
lated by testing two-fold dilutions of antibiotics ranging from 2 - 2,048µg/ml and
calculating geometric means from triplicate tests [1]. This necessarily constrains
the precision of the results, which may lead to some of the variation between the
predicted MICs and the experimental results. The level of precision of the Micro-
Gen model’s predicted MICs can be controlled by the user by choosing the amount
of different antibiotic concentrations to test. In the case of this study, incremental
antibiotic concentration increases of 20% were used. Although greater precision
can be obtained from experimental results by similarly testing more concentrations
of antibiotic, due to logistical constraints often only two-fold dilution steps are used
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in the broth dilution process.
5.3 Kinetic Parameters
The pharmacokinetic parameters dictating the interactions of the antibiotic
molecules with β-lactamase enzymes in the environment and with penicillin-
binding protein 2a in the bacterial cell are the key determinants of antibiotic efficacy
in the model. In order to explore the impact of these parameters on treatment out-
come, a number of simulations were carried out over a range of parameter values.
Figure 5.5 gives a general overview of how the Minimum Inhibitory Concentration
of a drug is influenced by the kinetic parameters.
It can be seen that the k2/Kd ratio, which is a measure of the antibiotic effi-
cacy at inhibiting PBP2a function, has the most pronounced impact on the MIC
of an antibiotic. The relative contribution of the β-lactamase reaction is less pro-
nounced. It does have a significant impact at higher values of kcat/KM higher than
107. However, in nature the catalytic efficiencies of β-lactamase enzymes have gen-
erally been found to be <107. For example, the kcat/KM values for type A MRSA
β-lactamase range from 3.3 x 106 M−1 s−1 against penicillin G to 2.2 x 103 M−1 s−1
against cephalothin. There may be some biological/physical constraints that limit
the development of more catalytically efficient β-lactamase enzymes, despite the
clear fitness advantage they would produce in the presence of β-lactam antibiotics.
The results in Figure 5.5 indicate that there would be a strong selective advan-
tage for the evolution of PBP2a variants with reduced k2/Kd values, when exposed
to antibiotics over prolonged periods of time. To a certain extent this has been the
case, such as in the case of methicillin antibiotic which has been shown to have
a k2/Kd value as low as 0.39 versus PBP2a [78]. However, in the case of the β-
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Figure 5.5: Surface plot of predicted Minimum Inhibitory Concentrations of β-
lactam antibiotics over range of values for kcat/KM and k2/Kd. kcat/KM is a measure
of the catalytic efficiency of β-lactamase enzyme at cleaving antibiotic molecules.
k2/Kd is a measure of antibiotic efficacy at inhibiting PBP2a function.
lactamase-sensitive antibiotic penicillin G this value is 12.0 [78]. These differences
may be due again to different biological constraints on the evolution of resistance
and/or differences in the patterns of exposure to the antibiotics.
Figure 5.6 represents another way of viewing the data recorded in figure 5.5. In
order to more clearly visualise the impact of the β-lactamase reaction kinetics on the
MIC, the data has been normalised to represent the relative MICs at different values
of kcat/KM . It can be seen that bacterial strains with a lower k2/Kd value respond
poorly to increases in the kcat/KM . For example, with a k2/Kd value of < 0.24, there
is no visible increase in the MIC over the range of kcat/KM values tested. Examples
of antibiotics which might exhibit this behaviour are the cephalosporin antibiotics,
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as well as imipenem and methicillin.
This indicates that there would not be significant selective pressure to evolve
more efficient β-lactamases when the k2/Kd value for the PBP2a reaction is low.
This agrees with experimental studies of several types of β-lactamase enzymes
from MRSA bacteria that have been shown to cleave cephalosporin antibiotics (low
k2/Kd) poorly relative to penicillin G [19]. The fact that they have not evolved
greater specificities for cephalosporin antibiotics may be because there would be
little or no significant fitness advantage conferred. On the other hand, there would
be a clear selective advantage for strains of MRSA with higher catalytic efficiencies
against penicillin G.
The results in figure 5.7 display the impact of changing k2/Kd on the MIC output.
There is a clear linear relationship between the log k2/Kd and the log relative MIC,
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Figure 5.7: Effect of varying second order rate constant (k2/Kd) of PBP2a-antibiotic
reaction on minimum inhibitory concentration of antibiotic with different kcat/KM
values (10.0 - 2.62 x 106).
with the kcat/KM parameters influencing the slope of the line. This indicates that
there is selective pressure to evolve PBPs with a lower k2/Kd value in the presence
of β-lactam antibiotics. This is to be expected since the PBP2a binding reaction
is crucial for the mode of action of β-lactam antibiotics. The change in the MIC
is inversely proportional to the change in the k2/Kd when the value of kcat/KM is
<105. For example, with a kcat/KM value of 1.64 x 105, reducing the k2/Kd value
from 1000.0 to 0.06 (16,393-fold decrease) results in a 15,319-fold increase in the
MIC.
In the following sections, a more detailed examination of the effect of the kinetic
parameters on survival in the presence of antibiotics will be carried out with refer-
ence to the antibiotics penicillin G, ampicillin and cephalothin, for which detailed
experimental estimates of their kinetic parameters versus PBP2a and two important
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types of β-lactamase are available.
5.3.1 Catalytic Efficiency of β-lactamase
The effects of Type A and Type C β-lactamases on the efficacies of penicillin G,
ampicillin and cephalothin were examined by exploring the relationship between
the length of time growth was inhibited by the antibiotics and the catalytic efficiency
(kcat/KM ) of the enzyme at hydrolytically cleaving the β-lactam ring (Fig. 5.8). The
inhibition time of an antibiotic is a convenient measure of antibiotic efficacy.
The catalytic efficiencies of the β-lactamase enzymes were varied over the range
102 - 1010 M−1 s−1 and the relative length of time growth was inhibited by each an-
tibiotic plotted. The length of time growth is inhibited by an antibiotic is displayed
relative to its inhibition time when the default (experimentally estimated) kinetic
parameter values are used as input (Fig. 5.8). There are strong negative correla-
tions between log β-lactamase efficiency (kcat/KM ) and inhibition time for both
penicillin G and ampicillin (r<−0.9, p< 0.01), and a weaker but still significant
(p< 0.01) correlation with cephalothin inhibition time (Type A: r =−0.803, Type
C: r =−0.774). Correlation analyses to calculate the Pearson correlation coefficient
(r) and two-tailed significance level (P) were carried out using SPSS statistical anal-
ysis software v11.0 (SPSS Inc., Chicago, IL, USA).
When correlation analyses are restricted to the smaller, but more biologically
realistic, range of catalytic frequencies 102 - 106 M−1 s−1 there is no correlation
between inhibition time and log kcat/KM for cephalothin over this range (r = 0.0).
On the other hand, for penicillin G and ampicillin there are still significant neg-
ative correlations present (r< -0.85, p< 0.01). These results agree qualitatively
with tests comparing antibiotic administered on its own and in conjunction with a
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β-lactamase inhibitor sulbactam [1]. The inhibitor sulbactam competes with an-
tibiotic molecules for binding to β-lactamase, effectively reducing the rate of hy-
drolytic activity of the enzyme against the antibiotic molecules (i.e. equivalent to
a reduced kcat/KM ). Norris et al. (1994) recorded a significant increase in antibi-
otic efficacy for penicillin and ampicillin in the presence of β-lactamase inhibitor,
whereas cephalothin was unaffected.
5.3.2 PBP2a Interactions
The other major mechanism of resistance characteristic of MRSA bacteria is the
expression of PBP2a protein in the cell membrane, which has decreased binding
affinity for β-lactam antibiotics. The role of PBP2a binding efficiency in influenc-
ing the outcome of treatment was also investigated across the three different types of
MRSA strains. The second order rate constant (a measure of inhibition efficiency)
for the reaction between antibiotic and PBP2a in MRSA was varied over a range of
several orders of magnitude for the antibiotics (Fig. 5.9).
There is a strong positive correlation between the binding efficiency of PBP2a
and the inhibition time for all the antibiotics against the three types of MRSA
(r< 0.9 and p< 0.01). However, there is a steeper increase in the inhibition time
of cephalothin relative to penicillin G and ampicillin when treating the Type A and
Type C β-lactamase producing strains (up to 4-fold difference in slope of fitted lin-
ear regression lines). This difference is much less pronounced in the case of the
β-lactamase-negative strain (< 2-fold difference in slope).
Once again, these results are in qualitative agreement with experimental find-
ings comparing MRSA bacterial strains (low k2/Kd) with methicillin-susceptible S.
aureus (MSSA) strains (high k2/Kd) [3, 2]. Miller et al. (2005) showed a signifi-
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cant increase in cephalothin efficacy between the MRSA and MSSA strains which
agrees with the results from Figure 5.9. The results from Malouin et al. (2003)
showed no significant difference in the antibiotic efficacies for penicillin/ampicillin
when comparing β-lactamase-positive MRSA and MSSA strains, but there was a
significant increase when comparing β-lactamase-negative strains. This is also in
agreement with Micro-Gen’s predictions from Figure 5.9. The model didn’t show
a notable increase in penicillin/ampicillin efficacy for β-lactamase-positive strains
unless k2/Kd was increased >104-fold over their experimentally estimated natural
values [78].
5.3.3 Discussion
For both type A and type C β-lactamases, if the catalytic efficiency against
cephalothin is varied by up to three orders of magnitude over the current natural
level, there is little discernible difference to the inhibition time (<1% difference).
This could indicate why both Type A and Type C β-lactamases have relatively low
rates of hydrolysis of cephalothin, compared to penicillin G: bacterial cells express-
ing more efficient β-lactamase against cephalothin would not have a significant evo-
lutionary fitness advantage. By contrast, for penicillin G and ampicillin, over the
same range of catalytic efficiencies, there is a steep decrease in the inhibition times
that strongly correlates with the catalytic efficiency. This suggests there would be
positive selective pressure for MRSA strains expressing more catalytically efficient
β-lactamases when exposed to penicillin G or ampicillin over extended periods of
time.
Figure 5.9 displays the results of varying the second order rate constant (k2/Kd)
of the reaction between antibiotic and PBP2a in the cell membrane. As this value
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is increased, the inhibition times of the antibiotics also increase, as expected since
the damage they inflict on the bacterial cell is proportional to their ability to bind
to and inhibit PBP2a function. However, the slope of the curve for cephalothin is
significantly steeper than either penicillin G or ampicillin when strains of MRSA
expressing either Type A or Type C β-lactamase are tested.
This indicates that the PBP2a status of a bacterial cell may have a more marked
impact on the clinical outcome of cephalothin treatment than penicillin G or ampi-
cillin treatment, in β-lactamase expressing strains. This agrees with experimental
studies which have shown that the MICs for penicillin/ampicillin are the same in
either MRSA (PBP2a-positive, low k2/Kd) or MSSA (PBP2a-negative, high k2/Kd)
strains of β-lactamase-producing bacteria. By contrast, there is a marked difference
recorded experimentally (>100-fold) in the MIC of cephalothin between PBP2a-
positive and PBP2a-negative strains [3].
When a β-lactamase-negative strain of MRSA is tested, on the other hand, the
profiles of penicillin G and ampicillin match cephalothin more closely, i.e. efficacy
is inversely proportional to PBP2a binding affinity. This is because the β-lactamase
enzyme is not present to limit the efficacies of the antibiotics. Since the β-lactamase
status and production rate can vary considerably across different strains of MRSA,
it is important to be able to predict quantitatively how these differences will affect
the treatment response in a particular infection.
5.4 Conclusions and Future Work
Traditional methods of measuring antibiotic efficacy such as the Minimum In-
hibitory Concentration are insufficient for understanding the complex dynamics that
lead to the rapid development and spread of antibiotic resistance within bacterial
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populations. However, the ability to investigate the relationship between individual
molecular components of the system and the overall treatment outcome can lead to
a better understanding of how to optimize antibiotic performance and predict treat-
ment outcome. Micro-Gen can also be used to indicate evolutionary pathways or
dead-ends that may exist for bacteria in response to antibiotic exposure.
Future work will include using the model to investigate the system dynamics of
combination therapy with multiple classes of antibiotic. It can also be used to test
hypothetical scenarios by varying the parameters of existing antibiotics to explore
how potential novel compounds might act. It is a useful tool for the rapid screening
of drug compounds against a diverse range of S. aureus strains in simulated culture
conditions. The agent-based approach is also suitable for modelling the evolution
of antibiotic resistance over time by incorporating genetic components into the bac-
terial agents. This would allow both the temporal and spatial dynamics of antibiotic
resistance development to be examined.
Another important future aim of the Micro-Gen project is to model β-lactamase-
dependent pro-drug delivery systems. Under these systems, a substrate-like pro-
drug molecule containing the β-lactam ring structure undergoes therapeutic activa-
tion catalysed by β-lactamases to achieve selective release of a cytotoxic antimi-
crobial agent [79, 80]. Micro-Gen would be a useful tool to examine the dynamics
of this system of activation and assess its therapeutic potential from a theoretical
standpoint. This will be the subject of the next chapter of this thesis.
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Figure 5.8: Predicted effects of varying catalytic efficiencies (kcat/KM ) of Type A
(A) and Type C (B) β-lactamases on relative inhibition times of antibiotics. Inhi-
bition times expressed relative to results when naturally occurring kcat/KM values
used (see Table 5.3). Data points represent means of three replicate simulations.
Dosage: Pen = 71.3µg/ml; Amp = 53.5µg/ml; Ceph = 103.1µg/ml.
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Figure 5.9: Predicted effects of varying second order rate constant (k2/Kd) of
PBP2a-Antibiotic reaction on relative inhibition times for Type A (A), Type C
(B) and β-lactamase-negative (C) MRSA strains. Inhibition times expressed rel-
ative to result when naturally occurring k2/Kd value used (see Table 5.3). Data
points represent means of three replicate simulations. Dosage: Pen = 71.3µg/ml;
Amp = 53.5µg/ml; Ceph = 103.1µg/ml.106
Table 5.3: Inputted parameter values for simulations of antibiotic interactions with
MRSA bacteria in Micro-Gen model. b.u. = biomass units; loop = program loop
(∼2 s in real time)
Type of Entity Parameters (units) Input Value
Environment
Patch area (b.u.) 20000
Patch nutrient level (b.u.) 80000
Diffusion co-efficient 0.1
Bacterial Cell
Generation time (min) 29
Threshold for division (b.u.) 10000
Nutrient intake (b.u. loop−1) 10.0
Survival cost (b.u. loop−1) 0.2
Stationary phase relative metabolic rate 0.2
Lag phase length (min) 63
β-lactamase production rate (µM s−1):
Type A 3.28 x 10−7
Type C 1.62 x 10−7
β-lactamase production cost (b.u.) 0.1
β-lactamase
Molecular weight (Da) 30000
Half-life (s) 53640
kcat (s−1): Type A Type C
Penicillin G 171.0 210.0
Ampicillin 308.0 355.0
Cephalothin 0.015 0.095
KM (µM): Type A Type C
Penicillin G 51.1 55.9
Ampicillin 255.0 122.0
Cephalothin 6.8 5.2
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Table 5.4: Inputted kinetic parameter values (k2, Kd), molecular weight (MR)
and half-life parameters for simulations of antibiotic interactions with penicillin-
binding protein 2a (PBP2a) in MRSA bacteria [1 - 8]. For diagrams of the chemical
structures of these antibiotics see figures 5.10 & 5.11
Antibiotic k2 Kd MR Half-life
(s−1) (µM) (Da) (s)
Cefotaxime 0.00035 586 455.47 3600
Ceftazidime 0.001 671 546.58 6840
Cephalothin 0.00115 586 396.44 1800
Cefoxitin 0.001162 586 427.45 2520
Cefepime 0.0015 1618 480.56 7200
Cephaloridine 0.0024 586 415 3660
Oxacillin 0.0016 180 401.44 1800
Ampicillin 0.0047 495 349.41 3600
Methicillin 0.0083 16900 380.42 3600
Penicillin G 0.185 15400 334.39 2520
Imipenem 0.0017 603 299.35 3600
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A. Cefotaxime B. Ceftazidime
C. Cephalothin D. Cefoxitin
E. Cefepime D. Cephaloridine
Figure 5.10: Diagrams of the chemical structures of the cephalosporin antibiotics
listed in Table 5.4. Structures derived from the on-line cheminformatics database
DrugBank [57].
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A. Oxacillin B. Ampicillin
C. Methicillin D. Penicillin G
E. Imipenem
Figure 5.11: Diagrams of the chemical structures of the penicillin antibiotics,
oxacillin, ampicillin, penicillin G and methcillin, and the carbapenem antibiotic,
imipenem (see Table 5.4). Structures derived from the on-line cheminformatics
database DrugBank [57].
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CHAPTER 6
PRO-DRUG DELIVERY SYSTEM
6.1 Overview
One of the strengths of the computational approach towards studying bacteria-drug
interactions is the ability to model hypothetical scenarios and explore how potential
novel compounds might act. For example, there has been recent interest in alterna-
tive drug delivery systems to improve the specificity and efficacy of anti-microbial
drugs. One such example, is the β-lactamase dependent enzyme-catalysed thera-
peutic activation (ECTA) pro-drug delivery system. This approach attempts to ex-
ploit the presence of β-lactamase enzymes in many species of pathogenic bacteria
to deliver inactive precursors of harmful anti-microbial agents which specifically
target these bacteria.
The basic premise of this approach is that a substrate-like pro-drug molecule
containing a β-lactam promoiety structure is administered to treat an infection [91].
When it comes into contact with β-lactamase producing bacteria, it undergoes ther-
apeutic activation by cleavage of its β-lactam ring which causes selective release
of a cytotoxic anti-microbial agent [80, 79, 92]. Therefore, the presence of β-
lactamase enzymes effectively decreases the survival chances of bacterial cells,
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resulting in negative selective pressure for expression of these genes. This con-
trasts with the current situation where many common β-lactam drugs are rendered
ineffective by the action of β-lactamases.
The theory of a β-lactamase dependent pro-drug delivery system represents a
potentially promising approach for treating β-lactamase-producing bacterial infec-
tions. However, there are complex system dynamics involved that influence the ef-
fectiveness of this technique. For this reason, it is useful to carry out computational
investigations to understand how factors such as the kinetics of the β-lactamase/pro-
drug interaction influence treatment outcome.
Micro-Gen is well suited for such investigations as it incorporates a model of the
kinetics of β-lactam ring cleavage in antibiotic molecules. By reversing the effect of
this reaction, whereby the drug is rendered active (not inactive) by this interaction,
some interesting preliminary insights can be made into the type of system dynamics
that would be expected to take place in a pro-drug delivery system.
6.2 System Dynamics of Pro-Drug Delivery System
The pro-drug delivery system differs from the traditional method of applying a rel-
atively high dose of an active anti-microbial agent. Traditional antibiotics such as
penicillin G or cephalothin are administered in a pharmacologically active form,
which then degrades over time according to its natural half-life or is inactivated
by enzymes such as β-lactamases. A pro-drug, on the other hand, can be a rela-
tively inert molecule which only becomes pharmacologically active after a specific
activation event takes place.
It is possible that the pro-drug could have some pharmacological activity itself.
For example, in a β-lactamase-dependent pro-drug delivery system, the β-lactam
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ring structure in the pro-drug could interact with the penicillin-binding proteins in
the bacterial cell to inhibit cell growth. However, for the simulations carried out
here, the pro-drug is assumed to be in an inert, pharmacologically inactive form.
This is in order to assess the effectiveness of this delivery system without intro-
ducing any ambiguities into the system due to direct antimicrobial activity. The
simulated pro-drug only becomes active after interaction and successful cleavage
by a β-lactamase enzyme.
As a result of this, when the pro-drug is added to the system there is initially no
active anti-microbial agent present (no contamination through non-selective activa-
tion, such as chemical hydrolysis, is assumed). As described in chapter 3, when a
bacterial cell interacts with a β-lactam ring-containing molecule, β-lactamase en-
zyme production is triggered. This starts at a low rate which increases exponentially
until the full production rate is reached after about 80 minutes [59]. During this
period, there is a gradual increase in the concentration of activated antimicrobial
agents in the vicinity of the bacteria. When the concentration of active drug ex-
ceeds a threshold for activity then bacterial growth is inhibited. There is therefore
a time delay between the addition of a pro-drug and the accumulation of sufficient
activated drug molecules to inhibit growth. This does not occur with traditional
antibiotics, which immediately bind to bacterial cells upon first contact according
to their kinetic rules.
Figure 6.1 shows a sample concentration curve for activated anti-microbial
agent when it is added in pro-drug form to a simulated colony of MRSA (input
parameters listed in Table 6.2). There is a gradual increase in the active drug com-
pound until it crosses a certain threshold to cause inhibition of bacterial growth
(0.6 - 0.8µg/ml). Figures 6.1 also shows the effect of adding the active antimi-
crobial agent directly (not in pro-drug form) at a concentration (0.8µg/ml) that is
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Figure 6.1: Comparison of activities of hypothetical active antibiotic applied di-
rectly or in pro-drug form. Two simulations were carried out: one with 1.8 µg/ml
of pro-drug administered at time = 3.3 hours, and the other with 0.8 µg/ml of pre-
activated anti-microbial agent (antibiotic) added at time = 3.3 hours. There is a clear
delay in inhibition of bacterial growth by the pro-drug due to the requirement of a
β-lactamase-mediated activation step.
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above the threshold for inhibition of bacterial growth. There is a threshold in the
concentration of the active drug compound that must be reached to inhibit bacterial
growth, which is dependent on the pharmacological properties of the activated drug
molecule. This results in a delay, due to the β-lactamase-mediated activation step,
between administration of the pro-drug and inhibition of bacterial growth when
there is a sufficient concentration of activated drug available.
6.2.1 Kinetics Studies
The speed and efficiency of activation of the pro-drug is an important factor for
determining the efficacy of a pro-drug delivery system. A number of simulations
were carried out to examine the effects of several different parameters on the acti-
vation of the pro-drug and inhibition of bacterial growth by the activated product.
The same cellular parameters for representing β-lactamase-producing MRSA that
were used in previous chapters were applied in the simulations here (Table 6.2).
A hypothetical penicillin-based pro-drug was simulated, i.e. the kinetic parameter
values (kcat/KM ) for penicillin G were used to define the interaction between β-
lactamases and the pro-drug molecules. The kinetic values for penicillin G were
chosen because this represents a situation where the β-lactamase enzymes have a
high catalytic efficiency versus the sample pro-drug. This represents an optimal
situation in order to assess the potential of this approach.
The active drug agent that arises from cleavage of the hypothetical penicillin-
based pro-drug has kinetic parameters (k2/Kd) which determine the rate of binding
to the bacterial cell (Table 6.2). Although the same parameters (k2/Kd) that were
used to represent binding of a β-lactam antibiotic to PBP2a in the bacterial cell are
used, this does not mean that the activated antimicrobial agent represents a β-lactam
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Figure 6.2: Effect of catalytic efficiency (kcat/KM ) of β-lactamase enzyme on min-
imum inhibitory concentration (MIC) of pro-drug. Three different pro-drugs are
graphed which differ by the rate of binding of their activated anti-microbial agent
to the bacterial cell (k2/Kd of activated anti-microbial agent varied between 62.5 and
1000 M−1 s−1).
antibiotic. These parameters are simply used because they are a convenient way of
carrying out initial modelling experiments and visualise their outcomes. The spe-
cific target of the active drug is not specified. For the purposes of this investigation
this is sufficient since the aim of the study is to assess the pro-drug delivery system
rather than obtain a quantitative estimate of the efficacy of a specific pro-drug. This
would require the availability of the kinetic parameters related to the interaction of
the activated antimicrobial agent with its specific target in the bacterial cell. Please
note that since the activated drug is assumed to lack the β-lactam ring structure, it
is not subject to cleavage and re-inactivation by β-lactamases.
Figure 6.2 shows the results of experiments investigating the effect of the ki-
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netic parameters on the minimum inhibitory concentration (MIC) of the penicillin-
based pro-drug. Three hypothetical variations of the pro-drug were investigated,
which differed by the rate of binding of the activated anti-microbial agent to the
bacterial cell (k2/Kd = 62.5, 250, or 1000 M−1 s−1). The catalytic efficiency of the β-
lactamase enzyme (kcat/KM ) at cleaving and activating the pro-drug was assessed by
varying over a range of 105 - 108 for each pro-drug variant. As would be expected,
higher values for the catalytic efficiency result in a lower MIC for the pro-drug.
The pattern in Figure 6.2 is the reverse of the trend seen in Figure 5.6 for tra-
ditional β-lactam antibiotics. This is one of the reasons why there is interest in the
β-lactamase-dependent pro-drug delivery system. It would be expected that admin-
istration of β-lactamase-dependent pro-drugs could lead to evolutionary selective
pressure opposed to the current selective pressure exerted by β-lactam drugs.
However, it must be noted that for high catalytic efficiencies there is a leveling
of the rate of decrease in the MIC (Fig. 6.2). This fitness “plateau” could negate
the selective advantage of bacteria producing β-lactamases with lower catalytic ef-
ficiencies. For example, in Figure 6.2, there is a less than 50% decrease in the
MIC above a kcat/KM value of approximately 106. On the other hand, Figure 5.6
shows that increasing the kcat/KM above 106 for active β-lactam antibiotics (non
pro-drugs) results in a significant fitness advantage (up to 7-fold increase in MIC).
The dynamics between the negative selective pressure from pro-drugs and pos-
itive selective pressure from β-lactam antibiotics would be an important factor to
consider when assessing the possible evolution of drug resistance in bacteria in
response to these two therapeutic strategies. However, the complex interplay of
biophysical, pharmacokinetic, pharmacological and epidemiological factors which
would contribute to this are beyond the scope of this study. Nevertheless, this mod-
elling approach is useful for developing theories about how molecular parameters
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may contribute to the dynamics observed.
6.2.2 Half-Life
One of the most important parameters that limits the efficacy of both traditional
antibiotics and novel drug candidates such as pro-drugs, is the half-life of the
molecule. However, as demonstrated in Chapter 4, the impact of this parameter
can vary substantially depending on the type of antibiotic used. For example, the
efficacy of penicillin G was predicted to be relatively resistant to changes in its
half-life compared to cephalothin (Fig. 4.2). Since the half-life of a molecule can
vary dramatically depending on local environmental conditions, it is important to
determine its influence in order to attempt to predict treatment success.
For this reason, computational analyses were carried out to predict the im-
pact of this parameter on the pro-drug delivery system (Fig. 6.3). The half-life
for the penicillin-based hypothetical pro-drug was varied between 16 minutes and
2.8 hours, and the growth curve of the bacterial population plotted along with the
concentration curve of activated anti-microbial agent. As can be seen in the graphs,
there is a certain threshold above which the concentration of activated drug must
cross before inhibition of bacterial growth is observed (in this case, the threshold is
approximately 0.8µg/ml).
With a half-life of ≤16 minutes, the concentration of activated anti-microbial
agent never exceeds the threshold required for growth inhibition (Fig. 6.3A-B).
Therefore, the bacterial population follows the standard growth curve, eventually
entering the stationary phase due to nutrient limitations. However, when the half-
life of the pro-drug is increased to 1.4 hours or greater, then the required concentra-
tion of active drug compound is reached and the length of time growth is inhibited
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is determined by the rate at which this compound degrades over time.
The half-life of a pro-drug is therefore a very important parameter when deter-
mining its efficacy against β-lactamase-producing S. aureus bacteria. This system
is particulary sensitive to the half-life parameter because of the time delay between
administration of the pro-drug and activation of sufficient quantities of active agent
to inhibit growth. The length of time that the drug inhibits bacterial growth is also
directly influenced by the activated drug’s own half-life.
6.2.3 Diffusion Rate
The impact of diffusion on the activity and dynamics of the pro-drug delivery sys-
tem was also investigated. This is an important parameter to assess because the pro-
drug delivery system depends on the targeted release of active anti-microbial agents
in the close vicinity of bacterial cells. Micro-Gen does not represent the complex
flow dynamics experienced in the in vivo situation. However, the implementation
of an algorithm based on Fick’s First Law of diffusion allows some insights to be
obtained on the role of diffusion dynamics in the system (see chapter 3).
Figure 6.5 shows the impact of varying the rate of diffusion in the environment
on the activation and efficacy of a penicillin-based pro-drug. The rate of diffusion
was varied by modifying the user-defined diffusion coefficient (D) for Fick’s First
Law of diffusion (see Fig. 3.1). This is a system-level parameter that alters the rates
of diffusion of all the molecules (pro-drug, active drug, β-lactamase and nutrients)
in the environment, see Chap. 3. Higher values correspond to a more fluid/dynamic
environment whereas lower values result in a more viscous/inert environment. The
results from these simulations indicate that the rate of diffusion has an important
influence on the availability of activated pro-drug in the vicinity of the bacterial
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Figure 6.3: Effect of varying the half-life parameter for a penicillin-based pro-drug
on the inhibition of β-lactamase-producing S. aureus bacterial growth. The graphs
display the simulated log bacterial growth curve along with the concentration of
activated drug molecules (µg/ml). 1.8µg/ml pro-drug added at time = 3.3 hours. A.
Half-life = 16 min; B. Half-life = 1.4 h; C. Half-life = 2.8 h;
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Figure 6.4: Comparison of the local diffusion gradients of active antimicrobial
agents in the local environment of β-lactamase producing S. aureus cells for pro-
drug (A) and traditional β-lactam antibiotics (B). A. When administered in pro-
drug form the active antimicrobial agent concentration is highest in the vicinity of
the bacterial cells due to β-lactamase-mediated activation. B. For traditional β-
lactam antibiotics the concentration of active agent is depleted in the vicinity of the
bacterial cells due to inactivation by the β-lactamases.
cells as measured by the height of the peak in the concentration of activated anti-
microbial agent (Fig. 6.5).
With a lower diffusion rate, the concentration of activated anti-microbial agents
in the local vicinity of the bacterial cells increased more rapidly. This may be
explained by the fact that with higher diffusion rates, the rate of clearance of the
activated drug molecules from the vicinity of the bacterial cells would be quicker
(Fig. 6.4A). This type of behaviour would also be expected to occur in environments
where there is a high flow rate. The efficacy of the activated antimicrobial agents
depends on their ability to stay long enough in the vicinity of the bacterial cells to
bind to and inhibit growth.
The pro-drug delivery system results in higher concentrations of activated drug
molecules in the direct vicinity of the bacterial cells. The system is therefore sen-
sitive to any forces, such as diffusion or flow forces, that may result in dispersal of
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the activated compounds. It is important, therefore, to take this into account when
designing pro-drugs and try to take measures to minimize this such as, for exam-
ple, designing molecules that have a greater binding affinity or are electrostatically
attracted to the bacterial cells.
This problem is not so evident with traditional antibiotic approaches because
they usually involve the administration of relatively high doses of active anti-
microbial agent that are not specifically targeted to the local vicinity of the bacterial
cells. In fact for some types of β-lactam antibiotic, such as penicillin G, increas-
ing the diffusion rate results in increased antibiotic efficacy (Fig. 4.4). This could
be due to the fact that higher rates of diffusion results in dispersal of β-lactamase-
inactivated penicillin G in the vicinity of the bacterial cells and replacement by
active penicillin G from elsewhere in the environment - the reverse situation to the
pro-drug system (Fig. 6.4B).
6.2.4 β-lactamase Production Rate
It is clear that the β-lactamase production rate of the bacterial cells is an important
parameter to be considered when investigating the β-lactamase-dependent pro-drug
delivery system. The production rate can vary considerably between different bac-
terial strains, and this must be factored in when assessing the usefulness of this
drug delivery system. Figure 6.6 shows the growth dynamics of a bacterial popula-
tion when exposed to a penicillin-based pro-drug (1.8µg/ml), with the β-lactamase
production rate varied between 10−7 - 10−5 µM s−1 agent−1. For reference, the β-
lactamase production rate for naturally occurring Type A MRSA under these simu-
lation conditions was estimated to be 3.28 x 10−7 µM s−1 agent−1 (see chapter 3).
The results confirm the important role that the β-lactamase production rate has
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Figure 6.5: Effect of varying the user-defined diffusion parameter (D) for Fick’s
First Law of diffusion on the inhibition of β-lactamase-producing S. aureus bacte-
rial growth by a penicillin-based pro-drug. The graphs display the simulated log
bacterial growth curve along with the concentration of activated drug molecules
(µg/ml). 1.8µg/ml of pro-drug added at time = 3.3 hours. A. D = 0.001; B. D = 0.01;
C. D = 0.1.
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Figure 6.6: Effect of varying the β-lactamase production rate on the inhibition
of β-lactamase-producing S. aureus bacterial growth by a penicillin-based pro-
drug. The graphs display the simulated log bacterial growth curve along with
the concentration of activated drug molecules (µg/ml). 1.8µg/ml of pro-drug
added at time = 3.3 hours. A. Production Rate = 10−7 µM s−1 agent−1; B. Produc-
tion Rate = 10−6 µM s−1 agent−1; C. Production Rate = 10−5 µM s−1 agent−1.
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on the efficacy of the β-lactamase dependent pro-drug delivery system. For these
simulations, it is assumed that there is no contamination or spontaneous activation
of the active anti-microbial agent apart from activation by β-lactamase. In real life,
there may be some contamination with active compound that would lead to posi-
tive results even when treating β-lactamase-negative strains of bacteria. However,
this ambiguity can lead to problems when assessing the true effectiveness of the
approach.
The active drug concentration threshold required for inhibition of growth is ap-
proximately 0.8µg/ml. This threshold is determined by the minimum inhibitory
concentration of the activated antimicrobial agent. It is noteworthy however, that
even at high β-lactamase production rates (e.g. Fig. 6.6E) where the active drug
concentration remains above the threshold of inhibition for a longer period of time,
the length of time growth is inhibited is not significantly longer than at lower pro-
duction rates (Fig. 6.6C). The length of time growth is inhibited seems to be limited
by the half-life (2520 s) of the drug in this case (see Fig. 6.3).
6.3 Case Study: NB2001 & NB2030
In recent years, there has been increased interest in developing novel pro-drug
compounds for treating antibiotic resistant bacteria. Two compounds, called
NB2001 and NB2030, were recently developed that exploit the β-lactamase de-
pendent enzyme-catalysed therapeutic activation (ECTA) pro-drug strategy [8, 80].
The general structure of these compounds consists of a cephalosporin backbone
(cephalothin derivative for NB2001 and cefazolin derivative for NB2030) with an
antibacterial agent (triclosan) in pro-drug form at the 3’ position of the cephem nu-
cleus (Fig. 6.7) [8]. The antibacterial agent is released by β-lactamase-mediated
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Figure 6.7: Chemical structures of NB2001 (A), NB2030 (B) and triclosan (C).
They consist of a cephalosporin side chain (NB2001 = cephalothin, NB2030 = ce-
fazolin) at position C-7, along with the enoyl reductase inhibitor triclosan at the C-3
position of the cephem nucleus [80].
hydrolysis of the β-lactam ring in the pro-drug structure.
The active antibacterial agent released from NB2001 and NB2030 is triclosan,
which possesses broad-spectrum antimicrobial activity against both gram-positive
and negative bacteria [93]. It is commonly used in health-care products such as
handwash, toothpaste and surgical scrubs [94]. Triclosan has been shown to have
potent activity against S. aureus bacteria by binding to the enoyl-[acyl-carrier-
protein] reductase (FabI) enzyme involved in the bacterial fatty acid synthesis cycle
[81]. However, the complex interactions that triclosan has with the bacterial cell
which lead to its lethality have still not been fully elucidated [93].
In order to explore Micro-Gen’s usefulness as a tool for investigating the ef-
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fectiveness of the pro-drug strategy, information from the experimental studies of
NB2001 and NB2030 were used to develop a pro-drug model of their interactions
with S. aureus bacteria. The bacterial cellular parameters were maintained the same
as those used to represent Type A β-lactamase-producing MRSA in the previous
chapters, including the β-lactamase-production rate which was estimated in chap-
ter 3. The kinetic parameters for the interaction between Type A β-lactamase and
the pro-drug compounds NB2001/NB2030 were derived from the experimental lit-
erature (see Table 6.2) [80].
The mechanism of action of triclosan is less well understood than the traditional
β-lactam antibiotics. The main cellular target of triclosan is believed to be the
FabI enzyme of the fatty acid biosynthetic pathway (see above). Therefore, an
abstract representation of triclosan is incorporated in the model by using the pre-
steady state reaction kinetic parameters (k2/Kd) to describe the binding of triclosan
in the bacterial cell to FabI enzyme and concomitant inhibition of bacterial growth
(equation 3.1). This is a simplistic but reasonable representation of the mode of
action of triclosan for the objectives of this study aiming at evaluating the pro-drug
delivery system.
The kinetic parameter values (k2/Kd) that determined triclosan’s interaction with
the bacterial cell were estimated by fitting the values to the experimental MIC esti-
mates determined from the literature [80]. These were maintained constant across
all the simulations carried out in order to assess the effects of changes to the pro-
drug delivery system.
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6.3.1 MIC Test Results
The in vitro activities of NB2001 and NB2030 (as well as the active antimicrobial
agent triclosan on its own and a cephalosporin antibiotic cephalothin) against S. au-
reus bacteria from the experimental literature were compared with predicted values
from Micro-Gen (Table 6.1) [80]. Predicted values where a specified percentage of
contamination with free triclosan was assumed were also included. The percentage
of contamination was derived from the experimental results of high-pressure liquid
chromatography (HPLC) tests documented in the original experimental study [80].
Table 6.1: Comparison of predicted MICs (with and without contamination with
free triclosan) from Micro-Gen model and experimentally determined MICs for
the pro-drugs NB2001 and NB2030, as well as triclosan and cephalothin, versus
Type A β-lactamase-producing MRSA bacteria. Percentage contamination with
free triclosan: NB2001 = 4 %, NB2030 = 1 %.
Antimicrobial Pred MIC Pred (Contam) MIC Exp MIC
Drug (µg/ml) (µg/ml) (µg/ml)
NB2001 0.0014 0.001 0.0002 - 0.002
NB2030 0.0003 0.0003 0.0002 - 0.004
Triclosan 0.0001 NA ≤0.0002
Cephalothin 103.1 NA 64
The experimental estimates of the MICs for NB2001 and NB2030 vary greatly
between different strains of S. aureus, which makes it difficult to verify the exper-
imental predictions with a high degree of accuracy. In particular, the β-lactamase
production rates for the strains used in the experimental analysis were only qualita-
tively estimated by a colourimetric test with nitrocefin [80]. However, given these
limitations, it is still encouraging that the predicted MICs for NB2001 and NB2030
were within the range of values recorded in the experimental study.
The model also provided a means to assess the impact of potential contamina-
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Figure 6.8: Predicted effect of varying percentage contamination with free tri-
closan (0% = pure pro-drug, 100% = pure triclosan) on Minimum Inhibitory Con-
centrations (MICs) of NB2001 and NB2030 versus Type A β-lactamase-producing
MRSA bacteria. Simulated drug compounds were added after 3.3 hours of incuba-
tion, during the exponential phase of bacterial growth.
tion with free triclosan on the MICs of the pro-drugs. For example, the level of
contamination in NB2001 was estimated experimentally to be 4 %. The Micro-Gen
model predicts that this level of contamination would account for approximately a
30 % decrease in the MIC compared to pure NB2001 (0.0010 versus 0.0014µg/ml).
On the other hand, the 1 % contamination found in NB2030 was predicted to not
have a detectable effect on its MIC.
Due to the inherent problem of contamination in pro-drug preparations it is
useful to be able to quantify how this might distort MIC determinations. Theoret-
ical modelling of the drug compounds can provide a means to estimate this effect.
Figure 6.8 shows the effect of varying the percentage of free triclosan contami-
nation between 1 - 100 %, where 100 % represents pure triclosan. Since triclosan
has very potent antibacterial activity (MIC≤ 0.0002µg/ml), the results of MIC de-
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terminations for the pro-drugs can be sensitive to contamination or β-lactamase-
independent hydrolysis.
In the case of NB2001, there is a strong negative correlation between the MIC
and the proportion of contamination with free triclosan (r =−0.997, p< 0.01).
However, the MIC of NB2030 is less sensitive to distortion by the presence of
free triclosan, although there is still a significant negative correlation (r =−0.868,
p = 0.011) This is because the catalytic efficiency (kcat/KM ) of the β-lactamase en-
zyme versus NB2030 is ten-fold higher than NB2001, and therefore the availability
of activated triclosan is less of a limiting factor on the efficacy.
If there is a high amount of contamination, then this can lead to mislead-
ing results. For example, NB2001 and NB2030 were found to have lower ex-
perimental MICs (0.0002µg/ml) against S. aureus strain 29213 than strain PC1
(NB2001 = 0.002µg/ml; NB2001 = 0.004µg/ml) [80]. This was in spite of the fact
that strain PC1 had a higher β-lactamase production rate, and therefore would be
expected to have a lower MIC. Differences in the level of contamination with free
triclosan (or non-β-lactamase-mediated activation) could not be ruled out as a cause
for this behaviour, and it highlights the importance of contamination studies when
assessing the efficacy of a pro-drug treatment strategy.
6.3.2 Sensitivity Analyses
The β-lactamase enzyme catalysed therapeutic activation (ECTA) pro-drug strat-
egy employed by NB2001 and NB2030 means that their efficacy is strongly depen-
dent on the β-lactamase status of the bacterial cells being treated. This approach
is designed to be particularly effective against β-lactamase over-expressing cells.
This dependence on the β-lactamase status of the cells is illustrated in Figure 6.9
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Figure 6.9: Predicted effect of β-lactamase production rate on minimum inhibitory
concentrations (MIC) of NB2001 and NB2030 versus simulated β-lactamase-
producing S. aureus bacteria. Free triclosan (which is unaffected by β-lactamase)
is included as a control. Drug compounds were added after 3.3 hours of incubation,
during the exponential phase of bacterial growth.
where the simulated log MIC of each pro-drug is graphed against a range of differ-
ent β-lactamase production rate values. There is a significant negative correlation
between the β-lactamase production rate and the MICs in the results (NB2001:
r =−0.993, p = 0.007; NB2030: r =−0.959, p = 0.041). This is to be expected given
the mechanism of activation is β-lactamase-dependent.
Variation between the graphs of NB2001 and NB2030 are due to differences
in the kinetic parameters of the enzymatic cleavage of the β-lactam ring. The cat-
alytic efficiency (kcat/KM ) of Staphylococcal Type A β-lactamase with NB2030 is
approximately ten-fold higher than with NB2001. As a result, the MIC for NB2030
is lower than NB2001 at any given β-lactamase production rate. However, at very
high production rates (e.g. >10−5 µM s−1 agent−1) the MIC of NB2030 begins
to be limited by the efficacy of the activated triclosan, and the graphs of the two
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Figure 6.10: The user-defined diffusion coefficient for Fick’s first law of diffusion
was varied over the range 0.001 - 0.2 to assess the relative impact of diffusion rate on
the minimum inhibitory concentration (MICs) of NB2001, NB2030 and triclosan
against β-lactamase-producing S. aureus bacteria. Drug compounds added after 3.3
hours of incubation, during the exponential phase of bacterial growth.
pro-drugs start to converge.
Another important factor that can influence pro-drug activity is the diffusion rate
in the environment. As discussed above, for the hypothetical penicillin-based pro-
drug, this can have an important impact on pro-drug efficacy. Figure 6.10 shows the
results of investigations on the effect it has on the MICs of the pro-drugs NB2001
and NB2030. For free triclosan, there is a significant negative correlation between
the MIC and the diffusion coefficient of Fick’s first law of diffusion (r =−0.989,
p = 0.011). This is probably due to faster transport of antibiotic via diffusion pro-
cesses to the interior of the colony resulting in better drug efficacy, or lower MIC
(see Fig. 6.4B).
However, when triclosan is administered in pro-drug form (NB2001 and
NB2030), there is no longer a significant negative correlation between the diffu-
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Figure 6.11: Predicted effect of varying the half-life on the minimum inhibitory
concentrations (MICs) of NB2001 and NB2030, and triclosan against simulated β-
lactamase-producing S. aureus bacteria in culture. Drug compounds were added
after 3.3 hours of incubation, during the exponential phase of bacterial growth.
sion coefficient and the MIC (NB2001: r = 0.829, p = 0.171; NB2030: r =−0.860,
p = 0.140). In fact, for NB2001 there is evidence of a positive correlation, although
it is not statistically significant. This may be because the increased diffusion rate
results in dispersal of the activated antimicrobial agent from the vicinity of the
bacterial cells (see Fig. 6.4A). The rate of β-lactamase-mediated activation of the
pro-drugs in the vicinity of the colony could also be a limiting factor in this case.
This is particularly evident with NB2001 because of the lower catalytic efficiency
(compared to NB2030) of the β-lactamase enzyme at cleaving it.
Finally, the impact of the half-life on the efficacy of the pro-drugs was also
investigated. For free triclosan, there is a significant negative correlation between
the half-life and the MIC of the drug (r =−0.961, p = 0.039). There is also a negative
correlation between the half-lives of NB2001 and NB2030 and their MICs but it is
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not statistically significant over the range of values tested (NB2001: r =−0.914,
p = 0.086; NB2030: r =−0.945, p = 0.055). When the half-life of the pro-drug is
below a certain threshold (in this case, approximately 1000 s), the pro-drug degrades
before the concentration of activated antimicrobial agent can reach the minimum
threshold for inhibition of growth (see Fig. 6.3). This threshold is influenced by the
time it takes for induction of β-lactamase expression in the bacterial cells to take
place.
6.4 Conclusions
The results presented here provide preliminary examinations of the pro-drug deliv-
ery system and how it influences the dynamics of bacterial growth and interactions
with drug molecules. These initial investigations show that the enzyme-catalysed
therapeutic activation (ECTA) pro-drug strategy represents a promising alternative
approach for treating β-lactamase expressing resistant pathogens. There are distinct
characteristics about the pro-drug system which distinguish it from the traditional
antibiotic approach, and it is worthwhile to explore these differences in order to
compare the strengths and weaknesses of each approach.
The dynamics of this system differ from the traditional β-lactam treatment strat-
egy and therefore could result in contrasting selective pressure on the bacteria (i.e.
selection against β-lactamase-producing strains of bacteria). However, a good the-
oretical understanding of the complex interactions involved must be developed in
order to prevent rapid development of resistance to these new types of drugs as has
occurred with many traditional antibiotics. This will require studies at various lev-
els, from high level population-based mathematical studies to low-level agent-based
models. However, as is the case for other antibiotics, these models require detailed
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biological information about the cellular and molecular components of the system
in order to correctly address the questions of how to optimize for treatment success.
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Table 6.2: Inputted parameter values for simulations of pro-drug interactions with
β-lactamase-producing S. aureus bacteria in Micro-Gen model. b.u. = biomass
units; loop = program loop (∼2 s in real time)
Type of Entity Parameters (units) Input Value
Environment
Patch area (b.u.) 20000
Patch nutrient level (b.u.) 80000
Diffusion co-efficient 0.1
Bacterial Cell
Generation time (min) 29
Threshold for division (b.u.) 10000
Nutrient intake (b.u. loop−1) 10.0
Survival cost (b.u. loop−1) 0.2
Stationary phase relative metabolic rate 0.2
Lag phase length (min) 63
β-lactamase production rate (µM s−1):
Type A 3.28 x 10−7
Type C 1.62 x 10−7
β-lactamase production cost (b.u.) 0.1
β-lactamase
Molecular weight (Da) 30000
Half-life (s) 53640
kcat (s−1):
Penicillin-based pro-drug 171.0
NB2001 1.01
NB2030 30.8
KM (µM):
Penicillin G-based pro-drug 51.1
NB2001 6.3
NB2030 20.0
Activated Pro-Drugs
Half-life (s)
Hypothetical compound 2520
Triclosan-equivalent 3600
k2 (s−1):
Hypothetical compound 0.185
Triclosan-equivalent 10.0
Kd (µM):
Hypothetical compound 1540
Triclosan-equivalent 10.0
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CHAPTER 7
CONCLUSIONS AND FUTURE WORK
7.1 Summary and Conclusions
An agent-based model of bacteria-antibiotic interactions has been developed, which
incorporates the antibiotic resistance mechanisms of MRSA bacteria. The model,
called the Micro-Gen Bacterial Simulator, uses information about the cell biology
of bacteria to produce global information about population growth in different envi-
ronmental conditions (Chap. 3). It facilitates a detailed systems-level investigation
of the dynamics involved in bacteria-antibiotic interactions and a means to relate
this information to traditional high-level properties such as the Minimum Inhibitory
Concentration (MIC) of an antibiotic (Chaps. 4 - 5).
The individual bacteria are represented by software agents that store physical
traits of the cells as well as behavioural rules associated with them. The culture en-
vironment is represented by a discrete, two-dimensional grid containing diffusible
elements such as nutrients, enzymes and antibiotics. Micro-Gen is also designed
to take advantage of high performance computing resources by including an im-
plementation of the Message Passing Interface (MPI) for running in parallel on
multiple computers.
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The model is highly adaptable and capable of being scaled up from lightweight
portable devices to high performance parallel computing machines. The user can
input parameters applicable to different species of bacteria by modifying low-level
cellular attributes such as size, growth rate, motility etc. However, as shown here,
it can also be adapted to incorporate detailed representations of specific antibiotic-
resistance strategies such as those employed by MRSA.
The two main resistance strategies against β-lactam antibiotics employed by
MRSA were incorporated into the model: β-lactamase enzymes which hydrolyt-
ically cleave antibiotic molecules, and penicillin-binding proteins (PBP2a) with
reduced binding affinities for antibiotics. In order to quantify the efficacy of the
antibiotics at inhibiting cell division, kinetic parameters describing the reactions
between antibiotics and PBP2a in the cell and β-lactamase cleavage of antibiotics
were derived from biological literature.
Tests with common β-lactam antibiotics indicate that the model can be used to
generate quantitatively accurate predictions of dosage requirements for antibiotics
against different strains of MRSA from basic cellular and biochemical information.
Furthermore, by varying key parameters in the model the relative impact of differ-
ent kinetic parameters associated with the two resistance mechanisms to β-lactam
antibiotics were investigated. The model has also been used to investigate the sys-
tem dynamics taking place within a population of bacteria. By varying properties
such as the diffusion rate, population size, β-lactamase production rate or antibiotic
half-life, the effects of these parameters on treatment response could be examined.
Traditional methods of measuring antibiotic efficacy such as the Minimum In-
hibitory Concentration are insufficient for understanding the complex dynamics that
lead to the rapid development and spread of antibiotic resistance within bacterial
populations. However, the ability to investigate the relationship between individ-
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ual molecular components of the system and the overall treatment outcome can
lead to a better understanding of how to optimize antibiotic performance and pre-
dict treatment outcome. The agent-based modelling approach represents another
computational tool set, in addition to existing pharmacokinetic-pharmacodynamic
mathematical models, for assessing the efficacy of novel drug compounds. Micro-
Gen can also be used to indicate evolutionary pathways or dead-ends that may exist
for bacteria in response to antibiotic exposure.
The model can also be extended to represent new classes of antimicrobial agents
and strategies for treating resistant bacteria. For example, the model has been used
to examine the system dynamics involved in the enzyme-catalysed therapeutic acti-
vation (ECTA) pro-drug strategy for treating antibiotic resistant bacteria (Chap. 6).
This involves the application of a substrate-like pro-drug molecule containing the
β-lactam ring structure, which undergoes therapeutic activation catalysed by β-
lactamase enzymes to achieve selective release of a cytotoxic antimicrobial agent.
The model was used to examine the dynamics of this system of activation and assess
its therapeutic potential from a theoretical standpoint.
7.2 Future Work
Micro-Gen can be used to test hypothetical scenarios by varying the parameters of
existing antibiotics to explore how potential novel compounds might act. It is a
useful tool for the rapid screening of drug compounds against a diverse range of S.
aureus strains in simulated culture conditions. Future work could also include using
the model to investigate the system dynamics of combination therapy with multiple
classes of antibiotic. The agent-based approach is also suitable for modelling the
evolution of antibiotic resistance over time by incorporating genetic components
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into the bacterial agents. This would allow both the temporal and spatial dynamics
of antibiotic resistance development to be examined.
Another important development of the model would be to expand the environ-
ment to represent three-dimensional space in order to model more complex spatially
structured microbial communities such as biofilms. Biofilms are complex aggrega-
tions of microbial cells that are characterised by their genetic diversity, structural
heterogeneity and complex cellular interactions. In these structured communities,
there can be highly heterogeneous localised niches where the chemistry varies dra-
matically over small distances. The agent-based approach is a powerful tool for
modelling interactions within a heterogeneous environment since the parameters
for the simulation are defined at the individual level.
Bacteria communicate with one another within biofilms in a process known as
quorum sensing, using chemical signalling molecules called auto-inducers. This
cell-to-cell communication allows a population of bacteria to coordinate the gene
expression, and therefore the behaviour, of the group. When bacteria exist in spa-
tially structured communities, the cell numbers can reach sufficiently high numbers
to induce a quorum sensing response. In the case of S. aureus bacteria, the change
from a commensal, non-invasive state to a pathogenic state is mediated by signalling
peptides that are part of the quorum sensing response.
The concentration of signals in a community is influenced by the production
rate and half-life of the signal molecule, the diffusion properties of the signal and
external hydrodynamic conditions. Micro-Gen already has systems to model these
properties with respect to free molecules (e.g. nutrients, enzymes, antibiotics) in
the environment. A diffusion algorithm implementing Fick’s First Law of diffusion
dictates the movement of molecules in the simulated environment. This will need to
be adapted and expanded to represent the more complex dynamics within the highly
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structured organisation of a biofilm community. This could be achieved by incorpo-
rating a more complex hydrodynamics algorithm to represent the flow of nutrients
and other molecules within the colony. The model represents a robust foundation
on which to build more complex models of real-world microbial communities such
as these.
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